

15. Piśmiennictwo

1. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2015; 313(6): 603–615, doi: [10.1001/jama.2014.18574](https://doi.org/10.1001/jama.2014.18574), indexed in Pubmed: [25668264](https://pubmed.ncbi.nlm.nih.gov/25668264/).
2. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016; 387(10022): 957–967, doi: [10.1016/S0140-6736\(15\)01225-8](https://doi.org/10.1016/S0140-6736(15)01225-8), indexed in Pubmed: [26724178](https://pubmed.ncbi.nlm.nih.gov/26724178/).
3. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. *JAMA*. 2017; 317(2): 165–182, doi: [10.1001/jama.2016.19043](https://doi.org/10.1001/jama.2016.19043), indexed in Pubmed: [28097354](https://pubmed.ncbi.nlm.nih.gov/28097354/).
4. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002; 360(9349): 1903–1913, indexed in Pubmed: [12493255](https://pubmed.ncbi.nlm.nih.gov/12493255/).
5. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. *Lancet*. 2017; 389(10064): 37–55, doi: [10.1016/S0140-6736\(16\)31919-5](https://doi.org/10.1016/S0140-6736(16)31919-5), indexed in Pubmed: [27863813](https://pubmed.ncbi.nlm.nih.gov/27863813/).
6. O'Donnell MJ, Chin SL, Rangarajan S, et al. INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet*. 2016; 388(10046): 761–775, doi: [10.1016/S0140-6736\(16\)30506-2](https://doi.org/10.1016/S0140-6736(16)30506-2), indexed in Pubmed: [27431356](https://pubmed.ncbi.nlm.nih.gov/27431356/).
7. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. *Lancet*. 2014; 383(9932): 1899–1911, doi: [10.1016/S0140-6736\(14\)60685-1](https://doi.org/10.1016/S0140-6736(14)60685-1), indexed in Pubmed: [24881994](https://pubmed.ncbi.nlm.nih.gov/24881994/).
8. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. *J Hypertens*. 2014; 32(12): 2285–2295, doi: [10.1097/HJH.0000000000000378](https://doi.org/10.1097/HJH.0000000000000378), indexed in Pubmed: [25255397](https://pubmed.ncbi.nlm.nih.gov/25255397/).
9. Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. *JAMA Intern Med*. 2017; 177(6): 792–799, doi: [10.1001/jama-internal.2017.0197](https://doi.org/10.1001/jama-internal.2017.0197), indexed in Pubmed: [28288249](https://pubmed.ncbi.nlm.nih.gov/28288249/).
10. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004; 364(9438): 937–952, doi: [10.1016/S0140-6736\(04\)17018-9](https://doi.org/10.1016/S0140-6736(04)17018-9), indexed in Pubmed: [15364185](https://pubmed.ncbi.nlm.nih.gov/15364185/).
11. Banegas JR, López-García E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. *Eur Heart J*. 2011; 32(17): 2143–2152, doi: [10.1093/eurheartj/ehr080](https://doi.org/10.1093/eurheartj/ehr080), indexed in Pubmed: [21471134](https://pubmed.ncbi.nlm.nih.gov/21471134/).
12. Chow CK, Teo KK, Rangarajan S, et al. PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. *JAMA*. 2013; 310(9): 959–968, doi: [10.1001/jama.2013.184182](https://doi.org/10.1001/jama.2013.184182), indexed in Pubmed: [24002282](https://pubmed.ncbi.nlm.nih.gov/24002282/).
13. Falaschetti E, Mindell J, Knott C, et al. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. *Lancet*. 2014; 383(9932): 1912–1919, doi: [10.1016/S0140-6736\(14\)60688-7](https://doi.org/10.1016/S0140-6736(14)60688-7), indexed in Pubmed: [24881995](https://pubmed.ncbi.nlm.nih.gov/24881995/).
14. Tocci G, Ferrucci A, Pontremoli R, et al. Blood pressure control in Italy: analysis of clinical data from 2005–2011 surveys on hypertension. *J Hypertens*. 2012; 30(6): 1065–1074, doi: [10.1097/HJH.0b013e3283535993](https://doi.org/10.1097/HJH.0b013e3283535993), indexed in Pubmed: [22573073](https://pubmed.ncbi.nlm.nih.gov/22573073/).
15. European Society of Cardiology, European Society of Hypertension, European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens*. 2003; 21(6): 1011–1053, doi: [10.1097/01.hjh.0000059051.65882.32](https://doi.org/10.1097/01.hjh.0000059051.65882.32), indexed in Pubmed: [12777938](https://pubmed.ncbi.nlm.nih.gov/12777938/).
16. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007; 25: 1105–1187.
17. Mancia G, Fagard R, Narkiewicz K, et al. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology, ESH/ESC Task Force for the Management of Arterial Hypertension, Task Force for the management of arterial hypertension of the European Society of Hypertension, Task Force for the management of arterial hypertension of the European Society of Cardiology. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013; 34(28): 2159–2219, doi: [10.1093/eurheartj/ehh151](https://doi.org/10.1093/eurheartj/ehh151), indexed in Pubmed: [23771844](https://pubmed.ncbi.nlm.nih.gov/23771844/).
18. Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. *J Hypertens*. 2016; 34(10): 1887–1920, doi: [10.1097/HJH.0000000000001039](https://doi.org/10.1097/HJH.0000000000001039), indexed in Pubmed: [27467768](https://pubmed.ncbi.nlm.nih.gov/27467768/).
19. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. *Lancet*. 2005; 365(9455): 217–223, doi: [10.1016/S0140-6736\(05\)17741-1](https://doi.org/10.1016/S0140-6736(05)17741-1), indexed in Pubmed: [15652604](https://pubmed.ncbi.nlm.nih.gov/15652604/).
20. Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). *Eur Heart J Cardiovasc Pharmacother*. 2017; 3(4): 235–250, doi: [10.1093/ehjcvp/pvx019](https://doi.org/10.1093/ehjcvp/pvx019), indexed in Pubmed: [28541499](https://pubmed.ncbi.nlm.nih.gov/28541499/).
21. Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. *JAMA Neurol*. 2017; 74(10): 1246–1254, doi: [10.1001/jamaneurol.2017.1658](https://doi.org/10.1001/jamaneurol.2017.1658), indexed in Pubmed: [28783817](https://pubmed.ncbi.nlm.nih.gov/28783817/).
22. Rovio S, Pahkala K, Nevalainen J, et al. Cardiovascular risk factors from childhood and midlife cognitive performance. *J Am Coll Cardiol*. 2017; 69(18): 2279–2289, doi: [10.1016/j.jacc.2017.02.060](https://doi.org/10.1016/j.jacc.2017.02.060).
23. Vishram JKK, Borglykke A, Andreasen AH, et al. MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MONica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. *Hypertension*. 2012; 60(5): 1117–1123, doi: [10.1161/HYPERTENSIONAHA.112.201400](https://doi.org/10.1161/HYPERTENSIONAHA.112.201400), indexed in Pubmed: [23006731](https://pubmed.ncbi.nlm.nih.gov/23006731/).
24. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. *Am J Hypertens*. 2007; 20(3): 338–341, doi: [10.1016/j.amjhyper.2006.08.004](https://doi.org/10.1016/j.amjhyper.2006.08.004), indexed in Pubmed: [17324749](https://pubmed.ncbi.nlm.nih.gov/17324749/).
25. Lawes CMM, Bennett DA, Parag V, et al. Asia Pacific Cohort Studies Collaboration, Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens*. 2003; 21(4): 707–716, doi: [10.1097/01.hjh.0000052492.18130.07](https://doi.org/10.1097/01.hjh.0000052492.18130.07), indexed in Pubmed: [12658016](https://pubmed.ncbi.nlm.nih.gov/12658016/).
26. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. *Circulation*. 1999; 100(4): 354–360, indexed in Pubmed: [10421594](https://pubmed.ncbi.nlm.nih.gov/10421594/).
27. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. *Lancet*. 2008; 371(9631): 2219–2221, doi: [10.1016/S0140-6736\(08\)60804-1](https://doi.org/10.1016/S0140-6736(08)60804-1), indexed in Pubmed: [18561995](https://pubmed.ncbi.nlm.nih.gov/18561995/).
28. Domanski M, Mitchell G, Pfeffer M, et al. MRFIT Research Group. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA*. 2002; 287(20): 2677–2683, indexed in Pubmed: [12020303](https://pubmed.ncbi.nlm.nih.gov/12020303/).
29. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. *Circulation*. 2009; 119(2): 243–250, doi: [10.1161/CIRCULATIONAHA.108.797936](https://doi.org/10.1161/CIRCULATIONAHA.108.797936), indexed in Pubmed: [19118251](https://pubmed.ncbi.nlm.nih.gov/19118251/).

30. Bhatt DL, Steg PG, Ohman EM, et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. *JAMA*. 2006; 295(2): 180–189, doi: [10.1001/jama.295.2.180](https://doi.org/10.1001/jama.295.2.180), indexed in Pubmed: [16403930](https://pubmed.ncbi.nlm.nih.gov/16403930/).
31. Mancia G, Facchetti R, Bombelli M, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. *Hypertension*. 2005; 45(6): 1072–1077, doi: [10.1161/01.HYP.0000165672.69176.ed](https://doi.org/10.1161/01.HYP.0000165672.69176.ed), indexed in Pubmed: [15867138](https://pubmed.ncbi.nlm.nih.gov/15867138/).
32. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. *N Engl J Med*. 2012; 366(4): 321–329, doi: [10.1056/NEJMoa1012848](https://doi.org/10.1056/NEJMoa1012848), indexed in Pubmed: [22276822](https://pubmed.ncbi.nlm.nih.gov/22276822/).
33. Aktas MK, Ozduran V, Pothier CE, et al. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. *JAMA*. 2004; 292(12): 1462–1468, doi: [10.1001/jama.292.12.1462](https://doi.org/10.1001/jama.292.12.1462), indexed in Pubmed: [15383517](https://pubmed.ncbi.nlm.nih.gov/15383517/).
34. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. *J Am Coll Cardiol*. 2009; 54(14): 1209–1227, doi: [10.1016/j.jacc.2009.07.020](https://doi.org/10.1016/j.jacc.2009.07.020), indexed in Pubmed: [19778661](https://pubmed.ncbi.nlm.nih.gov/19778661/).
35. Piepoli MF, Hoes AW, Agewall S, et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2016; 37(29): 2315–2381, doi: [10.1093/eurheartj/ehw106](https://doi.org/10.1093/eurheartj/ehw106), indexed in Pubmed: [27222591](https://pubmed.ncbi.nlm.nih.gov/27222591/).
36. Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. *J Hypertens*. 2015; 33(9): 1729–41; discussion 1741, doi: [10.1097/HJH.0000000000000701](https://doi.org/10.1097/HJH.0000000000000701), indexed in Pubmed: [26136207](https://pubmed.ncbi.nlm.nih.gov/26136207/).
37. van Dis I, Geleijnse JM, Boer JMa, et al. Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands. *Eur J Prev Cardiol*. 2014; 21(3): 377–383, doi: [10.1177/2047487312443485](https://doi.org/10.1177/2047487312443485), indexed in Pubmed: [22441305](https://pubmed.ncbi.nlm.nih.gov/22441305/).
38. Cuspidi C, Ambrosioni E, Mancia G, et al. APROS Investigators. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. *J Hypertens*. 2002; 20(7): 1307–1314, indexed in Pubmed: [12131527](https://pubmed.ncbi.nlm.nih.gov/12131527/).
39. Roman MJ, Pickering TG, Schwartz JE, et al. Association of carotid atherosclerosis and left ventricular hypertrophy. *J Am Coll Cardiol*. 1995; 25(1): 83–90, indexed in Pubmed: [7798531](https://pubmed.ncbi.nlm.nih.gov/7798531/).
40. Cuspidi C, Valerio C, Sala C, et al. Prevalence and correlates of multiple organ damage in a never-treated hypertensive population: role of ambulatory blood pressure. *Blood Press Monit*. 2008; 13(1): 7–13, doi: [10.1097/MBP.0b013e3282f13f36](https://doi.org/10.1097/MBP.0b013e3282f13f36), indexed in Pubmed: [18199918](https://pubmed.ncbi.nlm.nih.gov/18199918/).
41. Pontremoli R, Ravera M, Bezante GP, et al. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. *J Hypertens*. 1999; 17(7): 993–1000, indexed in Pubmed: [10419073](https://pubmed.ncbi.nlm.nih.gov/10419073/).
42. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. *Eur Heart J*. 2010; 31(7): 883–891, doi: [10.1093/eurheartj/ehp546](https://doi.org/10.1093/eurheartj/ehp546), indexed in Pubmed: [20034972](https://pubmed.ncbi.nlm.nih.gov/20034972/).
43. Perrone-Filardi P, Coca A, Galderisi M, et al. Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the European Society of Hypertension. *J Hypertens*. 2017; 35(9): 1727–1741, doi: [10.1097/HJH.0000000000001396](https://doi.org/10.1097/HJH.0000000000001396), indexed in Pubmed: [28767484](https://pubmed.ncbi.nlm.nih.gov/28767484/).
44. Stergiou GS, Alpert B, Mieke S, et al. A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. *J Hypertens*. 2018; 36(3): 472–478, doi: [10.1097/HJH.0000000000001634](https://doi.org/10.1097/HJH.0000000000001634), indexed in Pubmed: [29384983](https://pubmed.ncbi.nlm.nih.gov/29384983/).
45. Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. *Lancet*. 2012; 379(9819): 905–914, doi: [10.1016/S0140-6736\(11\)61710-8](https://doi.org/10.1016/S0140-6736(11)61710-8), indexed in Pubmed: [22293369](https://pubmed.ncbi.nlm.nih.gov/22293369/).
46. Fagard RH, De Cort P. Orthostatic hypotension is a more robust predictor of cardiovascular events than nighttime reverse dipping in elderly. *Hypertension*. 2010; 56(1): 56–61, doi: [10.1161/HYPERTENSIONAHA.110.151654](https://doi.org/10.1161/HYPERTENSIONAHA.110.151654), indexed in Pubmed: [20458003](https://pubmed.ncbi.nlm.nih.gov/20458003/).
47. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. *Am J Cardiol*. 2012; 109(5): 685–692, doi: [10.1016/j.amjcard.2011.10.025](https://doi.org/10.1016/j.amjcard.2011.10.025), indexed in Pubmed: [22169130](https://pubmed.ncbi.nlm.nih.gov/22169130/).
48. Myers MG. A Short History of Automated Office Blood Pressure — 15 Years to SPRINT. *J Clin Hypertens (Greenwich)*. 2016; 18(8): 721–724, doi: [10.1111/jch.12820](https://doi.org/10.1111/jch.12820), indexed in Pubmed: [27038200](https://pubmed.ncbi.nlm.nih.gov/27038200/).
49. Parati G, Pomidossi G, Casadei R, et al. Lack of alerting reactions to intermittent cuff inflations during noninvasive blood pressure monitoring. *Hypertension*. 1985; 7: 597–601.
50. Myers MG, Godwin M, Dawes M, et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. *Hypertension*. 2010; 55(2): 195–200, doi: [10.1161/HYPERTENSIONAHA.109.141879](https://doi.org/10.1161/HYPERTENSIONAHA.109.141879), indexed in Pubmed: [20038756](https://pubmed.ncbi.nlm.nih.gov/20038756/).
51. Wright JT, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015; 373(22): 2103–2116, doi: [10.1056/nejmoa1511939](https://doi.org/10.1056/nejmoa1511939).
52. Filipovský J, Seidlerová J, Kratochvíl Z, et al. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. *Blood Press*. 2016; 25(4): 228–234, doi: [10.3109/08037051.2015.1134086](https://doi.org/10.3109/08037051.2015.1134086), indexed in Pubmed: [26852625](https://pubmed.ncbi.nlm.nih.gov/26852625/).
53. Myers MG, Kaczorowski J, Dolovich L, et al. Cardiovascular Risk in Hypertension in Relation to Achieved Blood Pressure Using Automated Office Blood Pressure Measurement. *Hypertension*. 2016; 68(4): 866–872, doi: [10.1161/HYPERTENSIONAHA.116.07721](https://doi.org/10.1161/HYPERTENSIONAHA.116.07721), indexed in Pubmed: [27528062](https://pubmed.ncbi.nlm.nih.gov/27528062/).
54. Parati G, Stergiou G, O'Brien E, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. *J Hypertens*. 2014; 32(7): 1359–1366, doi: [10.1097/HJH.0000000000000221](https://doi.org/10.1097/HJH.0000000000000221), indexed in Pubmed: [24886823](https://pubmed.ncbi.nlm.nih.gov/24886823/).
55. Stergiou GS, Parati G, Vlachopoulos C, et al. Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement: current status and future directions. Position statement of the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. *J Hypertens*. 2016; 34(9): 1665–1677, doi: [10.1097/HJH.0000000000000969](https://doi.org/10.1097/HJH.0000000000000969), indexed in Pubmed: [27214089](https://pubmed.ncbi.nlm.nih.gov/27214089/).
56. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. *J Hypertens*. 2013; 31(9): 1731–1768, doi: [10.1097/HJH.0b013e328363e964](https://doi.org/10.1097/HJH.0b013e328363e964), indexed in Pubmed: [24029863](https://pubmed.ncbi.nlm.nih.gov/24029863/).
57. Parati G, Stergiou GS, Asmar R, et al. ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Hypertension Conference on Home Blood Pressure Monitoring. *J Hypertens*. 2008; 26(8): 1505–1526, doi: [10.1097/HJH.0b013e328308da66](https://doi.org/10.1097/HJH.0b013e328308da66), indexed in Pubmed: [18622223](https://pubmed.ncbi.nlm.nih.gov/18622223/).
58. Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. *J Hypertens*. 2012; 30(7): 1289–1299, doi: [10.1097/HJH.0b013e3283531eaf](https://doi.org/10.1097/HJH.0b013e3283531eaf), indexed in Pubmed: [22499289](https://pubmed.ncbi.nlm.nih.gov/22499289/).
59. Ward AM, Takahashi O, Stevens R, et al. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. *J Hypertens*. 2012; 30(3): 449–456, doi: [10.1097/HJH.0b013e32834e4aed](https://doi.org/10.1097/HJH.0b013e32834e4aed), indexed in Pubmed: [22241136](https://pubmed.ncbi.nlm.nih.gov/22241136/).
60. McManus R, Mant J, Bray E, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. *The Lancet*. 2010; 376(9736): 163–172, doi: [10.1016/s0140-6736\(10\)60964-6](https://doi.org/10.1016/s0140-6736(10)60964-6).

61. McManus RJ, Mant J, Haque MS, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMEN-SR randomized clinical trial. *JAMA*. 2014; 312(8): 799–808, doi: [10.1001/jama.2014.10057](https://doi.org/10.1001/jama.2014.10057), indexed in Pubmed: [25157723](https://pubmed.ncbi.nlm.nih.gov/25157723/).
62. Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. *PLoS Med*. 2017; 14(9): e1002389, doi: [10.1371/journal.pmed.1002389](https://doi.org/10.1371/journal.pmed.1002389), indexed in Pubmed: [28926573](https://pubmed.ncbi.nlm.nih.gov/28926573/).
63. Omboni S, Gazzola T, Carabelli G, et al. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. *J Hypertens*. 2013; 31(3): 455–67; discussion 467, doi: [10.1097/HJH.0b013e32835ca8dd](https://doi.org/10.1097/HJH.0b013e32835ca8dd), indexed in Pubmed: [23299557](https://pubmed.ncbi.nlm.nih.gov/23299557/).
64. Parati G, Omboni S. Role of home blood pressure telemonitoring in hypertension management: an update. *Blood Press Monit*. 2010; 15(6): 285–295, doi: [10.1097/MBP.0b013e328340c5e4](https://doi.org/10.1097/MBP.0b013e328340c5e4), indexed in Pubmed: [21084882](https://pubmed.ncbi.nlm.nih.gov/21084882/).
65. Gaborieau V, Delarche N, Gosse P. Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: correlation with target organ damage. *J Hypertens*. 2008; 26(10): 1919–1927, doi: [10.1097/HJH.0b013e32830c4368](https://doi.org/10.1097/HJH.0b013e32830c4368), indexed in Pubmed: [18806615](https://pubmed.ncbi.nlm.nih.gov/18806615/).
66. Clement DL, De Buyzere ML, De Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. *N Engl J Med*. 2003; 348(24): 2407–2415, doi: [10.1056/NEJMoa022273](https://doi.org/10.1056/NEJMoa022273), indexed in Pubmed: [12802026](https://pubmed.ncbi.nlm.nih.gov/12802026/).
67. Segà R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. *Circulation*. 2005; 111(14): 1777–1783, doi: [10.1161/01.CIR.0000160923.04524.5B](https://doi.org/10.1161/01.CIR.0000160923.04524.5B), indexed in Pubmed: [15809377](https://pubmed.ncbi.nlm.nih.gov/15809377/).
68. Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. *N Engl J Med*. 2018; 378(16): 1509–1520, doi: [10.1056/NEJMoa1712231](https://doi.org/10.1056/NEJMoa1712231), indexed in Pubmed: [29669232](https://pubmed.ncbi.nlm.nih.gov/29669232/).
69. Roush GC, Fagard RH, Salles GF, et al. ABC-H Investigators. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. *J Hypertens*. 2014; 32(12): 2332–40; discussion 2340, doi: [10.1097/HJH.0000000000000355](https://doi.org/10.1097/HJH.0000000000000355), indexed in Pubmed: [25333682](https://pubmed.ncbi.nlm.nih.gov/25333682/).
70. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. *Hypertension*. 2008; 51(1): 55–61, doi: [10.1161/HYPERTENSIONAHA.107.100727](https://doi.org/10.1161/HYPERTENSIONAHA.107.100727), indexed in Pubmed: [18039980](https://pubmed.ncbi.nlm.nih.gov/18039980/).
71. Parati G, Ochoa JE, Bilo G, et al. European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA). Hypertension in Chronic Kidney Disease Part 2: Role of ambulatory and home blood pressure monitoring for assessing alterations in blood pressure variability and blood pressure profiles. *Hypertension*. 2016; 67(6): 1102–1110, doi: [10.1161/HYPERTENSIONAHA.115.06896](https://doi.org/10.1161/HYPERTENSIONAHA.115.06896), indexed in Pubmed: [27141057](https://pubmed.ncbi.nlm.nih.gov/27141057/).
72. Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2015; 162(3): 192–204, doi: [10.7326/M14-1539](https://doi.org/10.7326/M14-1539), indexed in Pubmed: [25531400](https://pubmed.ncbi.nlm.nih.gov/25531400/).
73. Omboni S, Parati G, Palatini P, et al. Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation. *J Hypertens*. 1998; 16(6): 733–738, indexed in Pubmed: [9663912](https://pubmed.ncbi.nlm.nih.gov/9663912/).
74. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. *Circ Res*. 2015; 116(6): 1034–1045, doi: [10.1161/CIRCRESAHA.116.303755](https://doi.org/10.1161/CIRCRESAHA.116.303755), indexed in Pubmed: [25767288](https://pubmed.ncbi.nlm.nih.gov/25767288/).
75. Salles GF, Reboldi G, Fagard RH, et al. ABC-H Investigators. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the Ambulatory Blood Pressure Collaboration in Patients With Hypertension (ABC-H) Meta-Analysis. *Hypertension*. 2016; 67(4): 693–700, doi: [10.1161/HYPERTENSIONAHA.115.06981](https://doi.org/10.1161/HYPERTENSIONAHA.115.06981), indexed in Pubmed: [26902495](https://pubmed.ncbi.nlm.nih.gov/26902495/).
76. Mancia G. Short- and long-term blood pressure variability: present and future. *Hypertension*. 2012; 60(2): 512–517, doi: [10.1161/HYPERTENSIONAHA.112.194340](https://doi.org/10.1161/HYPERTENSIONAHA.112.194340), indexed in Pubmed: [22733459](https://pubmed.ncbi.nlm.nih.gov/22733459/).
77. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation*. 2003; 107(10): 1401–1406, indexed in Pubmed: [12642361](https://pubmed.ncbi.nlm.nih.gov/12642361/).
78. Parati G, Schillaci G. What are the real determinants of the ambulatory arterial stiffness index? *J Hypertens*. 2012; 30(3): 472–476, doi: [10.1097/HJH.0b013e3283509ae2](https://doi.org/10.1097/HJH.0b013e3283509ae2), indexed in Pubmed: [22317994](https://pubmed.ncbi.nlm.nih.gov/22317994/).
79. Kikuya M, Ohkubo T, Metoki H, et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. *Hypertension*. 2008; 52(6): 1045–1050, doi: [10.1161/HYPERTENSIONAHA.107.104620](https://doi.org/10.1161/HYPERTENSIONAHA.107.104620), indexed in Pubmed: [18981332](https://pubmed.ncbi.nlm.nih.gov/18981332/).
80. Mancia G, Zanchetti A. White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? *J Hypertens*. 1996; 14(9): 1049–1052, indexed in Pubmed: [8986902](https://pubmed.ncbi.nlm.nih.gov/8986902/).
81. Bobrie G, Clerson P, Ménard J, et al. Masked hypertension: a systematic review. *J Hypertens*. 2008; 26(9): 1715–1725, doi: [10.1097/HJH.0b013e3282fbcdf](https://doi.org/10.1097/HJH.0b013e3282fbcdf), indexed in Pubmed: [18698202](https://pubmed.ncbi.nlm.nih.gov/18698202/).
82. Mancia G, Bombelli M, Cuspidi C, et al. Cardiovascular Risk Associated With White-Coat Hypertension: Pro Side of the Argument. *Hypertension*. 2017; 70(4): 668–675, doi: [10.1161/HYPERTENSIONAHA.117.08903](https://doi.org/10.1161/HYPERTENSIONAHA.117.08903), indexed in Pubmed: [28847891](https://pubmed.ncbi.nlm.nih.gov/28847891/).
83. Parati G, Omboni S, Staessen J, et al. Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the ‘white-coat’ effect. Syst-Eur investigators. *J Hypertens*. 1998; 16(1): 23–29, indexed in Pubmed: [9533413](https://pubmed.ncbi.nlm.nih.gov/9533413/).
84. Banegas JR, Ruilope LM, de la Sierra A, et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. *Eur Heart J*. 2014; 35(46): 3304–3312, doi: [10.1093/eurheartj/ehu016](https://doi.org/10.1093/eurheartj/ehu016), indexed in Pubmed: [24497346](https://pubmed.ncbi.nlm.nih.gov/24497346/).
85. Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. *J Hypertens*. 2017; 35(4): 677–688, doi: [10.1097/HJH.0000000000001226](https://doi.org/10.1097/HJH.0000000000001226), indexed in Pubmed: [28253216](https://pubmed.ncbi.nlm.nih.gov/28253216/).
86. Briasoulis A, Androulakis E, Palla M, et al. White-coat hypertension and cardiovascular events: a meta-analysis. *J Hypertens*. 2016; 34(4): 593–599, doi: [10.1097/HJH.0000000000000832](https://doi.org/10.1097/HJH.0000000000000832), indexed in Pubmed: [26734955](https://pubmed.ncbi.nlm.nih.gov/26734955/).
87. Grassi G, Seravalle G, Trevano FQ, et al. Neurogenic abnormalities in masked hypertension. *Hypertension*. 2007; 50(3): 537–542, doi: [10.1161/HYPERTENSIONAHA.107.092528](https://doi.org/10.1161/HYPERTENSIONAHA.107.092528), indexed in Pubmed: [17620522](https://pubmed.ncbi.nlm.nih.gov/17620522/).
88. Mancia G. Clinical significance of white-coat hypertension. *J Hypertens*. 2016; 34(4): 623–626, doi: [10.1097/hjh.0000000000000879](https://doi.org/10.1097/hjh.0000000000000879).
89. Mancia G. White-coat hypertension: growing evidence in favour of its adverse prognostic significance. *J Hypertens*. 2017; 35(4): 710–712, doi: [10.1097/HJH.0000000000001289](https://doi.org/10.1097/HJH.0000000000001289), indexed in Pubmed: [28248898](https://pubmed.ncbi.nlm.nih.gov/28248898/).
90. Mancia G, Grassi G. The heterogeneous nature of white-coat hypertension. *J Am Coll Cardiol*. 2016; 68(19): 2044–2046, doi: [10.1016/j.jacc.2016.08.043](https://doi.org/10.1016/j.jacc.2016.08.043), indexed in Pubmed: [27810042](https://pubmed.ncbi.nlm.nih.gov/27810042/).
91. Asayama K, Li Y, Franklin SS, et al. Cardiovascular risk associated with white-coat hypertension: con side of the argument. *Hypertension*. 2017; 70(4): 676–682, doi: [10.1161/HYPERTENSIONAHA.117.08902](https://doi.org/10.1161/HYPERTENSIONAHA.117.08902), indexed in Pubmed: [28847889](https://pubmed.ncbi.nlm.nih.gov/28847889/).
92. Lurbe E, Torro I, Alvarez V, et al. Prevalence, persistence, and clinical significance of masked hypertension in youth. *Hypertension*. 2005; 45(4): 493–498, doi: [10.1161/01.HYP.0000160320.39303.ab](https://doi.org/10.1161/01.HYP.0000160320.39303.ab), indexed in Pubmed: [15767467](https://pubmed.ncbi.nlm.nih.gov/15767467/).
93. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. *Hypertension*. 2006; 47(5): 846–853, doi: [10.1161/01.HYP.0000215363.69793.bb](https://doi.org/10.1161/01.HYP.0000215363.69793.bb), indexed in Pubmed: [16567588](https://pubmed.ncbi.nlm.nih.gov/16567588/).
94. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of. *JAMA*. 2004; 291(11): 1342–1349, doi: [10.1001/jama.291.11.1342](https://doi.org/10.1001/jama.291.11.1342), indexed in Pubmed: [15026401](https://pubmed.ncbi.nlm.nih.gov/15026401/).
95. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normo-

- tension: a meta-analysis. *J Hypertens*. 2007; 25(11): 2193–2198, doi: [10.1097/HJH.0b013e3282ef6185](https://doi.org/10.1097/HJH.0b013e3282ef6185), indexed in Pubmed: [17921809](https://pubmed.ncbi.nlm.nih.gov/17921809/).
96. Franklin SS, Thijs L, Li Y, et al. International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators. Response to Masked hypertension in untreated and treated patients with diabetes mellitus: attractive but questionable interpretations and response to Is masked hypertension related to diabetes mellitus? *Hypertension*. 2013; 62(4): e23–e25, indexed in Pubmed: [24156104](https://pubmed.ncbi.nlm.nih.gov/24156104/).
 97. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. *N Engl J Med*. 2002; 347(11): 797–805, doi: [10.1056/NEJMoa013410](https://doi.org/10.1056/NEJMoa013410), indexed in Pubmed: [12226150](https://pubmed.ncbi.nlm.nih.gov/12226150/).
 98. Lindholt JS, Sogaard R. Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial. *Lancet*. 2017; 390(10109): 2256–2265, doi: [10.1016/S0140-6736\(17\)32250-X](https://doi.org/10.1016/S0140-6736(17)32250-X), indexed in Pubmed: [28859943](https://pubmed.ncbi.nlm.nih.gov/28859943/).
 99. Hodgkinson J, Mant J, Martin U, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. *BMJ*. 2011; 342: d3621, indexed in Pubmed: [21705406](https://pubmed.ncbi.nlm.nih.gov/21705406/).
 100. Vinyoles E, Felip A, Pujol E, et al. Spanish Society of Hypertension ABPM Registry. Clinical characteristics of isolated clinic hypertension. *J Hypertens*. 2008; 26(3): 438–445, doi: [10.1097/HJH.0b013e3282f3150b](https://doi.org/10.1097/HJH.0b013e3282f3150b), indexed in Pubmed: [18300853](https://pubmed.ncbi.nlm.nih.gov/18300853/).
 101. McManus RJ, Mant J. Do differences in blood pressure between arms matter? *Lancet*. 2012; 379(9819): 872–873, doi: [10.1016/S0140-6736\(11\)61926-0](https://doi.org/10.1016/S0140-6736(11)61926-0), indexed in Pubmed: [22293365](https://pubmed.ncbi.nlm.nih.gov/22293365/).
 102. McManus RJ, Mant J, Franssen M, et al. TASMINH4 investigators. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. *Lancet*. 2018; 391(10124): 949–959, doi: [10.1016/S0140-6736\(18\)30309-X](https://doi.org/10.1016/S0140-6736(18)30309-X), indexed in Pubmed: [29499873](https://pubmed.ncbi.nlm.nih.gov/29499873/).
 103. Le VV, Mitiku T, Sungar G, et al. The blood pressure response to dynamic exercise testing: a systematic review. *Prog Cardiovasc Dis*. 2008; 51(2): 135–160, doi: [10.1016/j.pcad.2008.07.001](https://doi.org/10.1016/j.pcad.2008.07.001), indexed in Pubmed: [18774013](https://pubmed.ncbi.nlm.nih.gov/18774013/).
 104. Holmqvist L, Mortensen L, Kanckos C, et al. Exercise blood pressure and the risk of future hypertension. *J Hum Hypertens*. 2012; 26(12): 691–695, doi: [10.1038/jhh.2011.99](https://doi.org/10.1038/jhh.2011.99), indexed in Pubmed: [22129608](https://pubmed.ncbi.nlm.nih.gov/22129608/).
 105. Parati G, Agostoni P, Basnyat B, et al. Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions. *European Heart Journal*. 2018; 39(17): 1546–1554, doi: [10.1093/eurheartj/ehx720](https://doi.org/10.1093/eurheartj/ehx720).
 106. Picone DS, Schultz MG, Otahal P, et al. Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses. *J Am Coll Cardiol*. 2017; 70(5): 572–586, doi: [10.1016/j.jacc.2017.05.064](https://doi.org/10.1016/j.jacc.2017.05.064), indexed in Pubmed: [28750701](https://pubmed.ncbi.nlm.nih.gov/28750701/).
 107. Herbert A, Cruickshank JK, Laurent S, et al. Reference Values for Arterial Measurements Collaboration. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. *Eur Heart J*. 2014; 35(44): 3122–3133, doi: [10.1093/eurheartj/ehu293](https://doi.org/10.1093/eurheartj/ehu293), indexed in Pubmed: [25112663](https://pubmed.ncbi.nlm.nih.gov/25112663/).
 108. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation*. 2006; 113(9): 1213–1225, doi: [10.1161/CIRCULATIONAHA.105.595496](https://doi.org/10.1161/CIRCULATIONAHA.105.595496), indexed in Pubmed: [16476843](https://pubmed.ncbi.nlm.nih.gov/16476843/).
 109. Vlachopoulos C, Aznaouridis K, O'Rourke MF, et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. *Eur Heart J*. 2010; 31(15): 1865–1871, doi: [10.1093/eurheartj/ehq024](https://doi.org/10.1093/eurheartj/ehq024), indexed in Pubmed: [20197424](https://pubmed.ncbi.nlm.nih.gov/20197424/).
 110. Lurbe E, Redon J. Isolated systolic hypertension in young people is not spurious and should be treated: con side of the argument. *Hypertension*. 2016; 68(2): 276–280, doi: [10.1161/HYPERTENSIONAHA.116.06548](https://doi.org/10.1161/HYPERTENSIONAHA.116.06548), indexed in Pubmed: [27324227](https://pubmed.ncbi.nlm.nih.gov/27324227/).
 111. McEnery CM, Franklin SS, Cockcroft JR, et al. Isolated systolic hypertension in young people is not spurious and should be treated: pro side of the argument. *Hypertension*. 2016; 68(2): 269–275, doi: [10.1161/HYPERTENSIONAHA.116.06547](https://doi.org/10.1161/HYPERTENSIONAHA.116.06547), indexed in Pubmed: [27324230](https://pubmed.ncbi.nlm.nih.gov/27324230/).
 112. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. *Circulation*. 1993; 88(4 Pt 1): 1444–1455, indexed in Pubmed: [8403291](https://pubmed.ncbi.nlm.nih.gov/8403291/).
 113. Cordero A, Morillas P, Bertomeu-Gonzalez V, et al. Prevalence of Peripheral Arterial Disease in Patients with Acute Coronary Syndrome Investigators. Clustering of target organ damage increases mortality after acute coronary syndromes in patients with arterial hypertension. *J Hum Hypertens*. 2011; 25(10): 600–607, doi: [10.1038/jhh.2010.109](https://doi.org/10.1038/jhh.2010.109), indexed in Pubmed: [21160527](https://pubmed.ncbi.nlm.nih.gov/21160527/).
 114. Greve SV, Blicher MK, Sehested T, et al. Effective risk stratification in patients with moderate cardiovascular risk using albuminuria and atherosclerotic plaques in the carotid arteries. *J Hypertens*. 2015; 33(8): 1563–1570, doi: [10.1097/HJH.0000000000000584](https://doi.org/10.1097/HJH.0000000000000584), indexed in Pubmed: [26103123](https://pubmed.ncbi.nlm.nih.gov/26103123/).
 115. de Simone G, Devereux RB, Izzo R, et al. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study. *J Am Heart Assoc*. 2013; 2(3): e000144, doi: [10.1161/JAHA.113.000144](https://doi.org/10.1161/JAHA.113.000144), indexed in Pubmed: [23744404](https://pubmed.ncbi.nlm.nih.gov/23744404/).
 116. Lønnebakken MT, Izzo R, Mancusi C, et al. Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network). *J Am Heart Assoc*. 2017; 6(3), doi: [10.1161/JAHA.116.004152](https://doi.org/10.1161/JAHA.116.004152), indexed in Pubmed: [28275070](https://pubmed.ncbi.nlm.nih.gov/28275070/).
 117. Volpe M, Battistoni A, Tocci G, et al. Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. *J Hypertens*. 2012; 30(6): 1056–1064, doi: [10.1097/HJH.0b013e3283525715](https://doi.org/10.1097/HJH.0b013e3283525715), indexed in Pubmed: [22573072](https://pubmed.ncbi.nlm.nih.gov/22573072/).
 118. Bacharova L, Schocken D, Estes EH, et al. The role of ECG in the diagnosis of left ventricular hypertrophy. *Curr Cardiol Rev*. 2014; 10(3): 257–261, indexed in Pubmed: [24827796](https://pubmed.ncbi.nlm.nih.gov/24827796/).
 119. Pahor M, Guralnik JM, Ambrosius WT, et al. LIFE study investigators. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. *JAMA*. 2014; 311(23): 2387–2396, doi: [10.1001/jama.2014.5616](https://doi.org/10.1001/jama.2014.5616), indexed in Pubmed: [24866862](https://pubmed.ncbi.nlm.nih.gov/24866862/).
 120. Lehtonen AO, Puukka P, Varis J, et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. *J Hypertens*. 2016; 34(5): 959–966, doi: [10.1097/HJH.0000000000000882](https://doi.org/10.1097/HJH.0000000000000882), indexed in Pubmed: [26886566](https://pubmed.ncbi.nlm.nih.gov/26886566/).
 121. Okin PM, Devereux RB, Jern S, et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. *JAMA*. 2004; 292(19): 2343–2349, doi: [10.1001/jama.292.19.2343](https://doi.org/10.1001/jama.292.19.2343), indexed in Pubmed: [15547161](https://pubmed.ncbi.nlm.nih.gov/15547161/).
 122. Okin PM, Oikarinen L, Viitasalo M, et al. LIFE Study Investigators. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). *Circulation*. 2009; 119(14): 1883–1891, doi: [10.1161/CIRCULATIONAHA.108.812313](https://doi.org/10.1161/CIRCULATIONAHA.108.812313), indexed in Pubmed: [19332468](https://pubmed.ncbi.nlm.nih.gov/19332468/).
 123. de Simone G, Izzo R, Chinali M, et al. Does information on systolic and diastolic function improve prediction of a cardiovascular event by left ventricular hypertrophy in arterial hypertension? *Hypertension*. 2010; 56(1): 99–104, doi: [10.1161/HYPERTENSIONAHA.110.150128](https://doi.org/10.1161/HYPERTENSIONAHA.110.150128), indexed in Pubmed: [20497990](https://pubmed.ncbi.nlm.nih.gov/20497990/).
 124. Bombelli M, Facchetti R, Cuspidi C, et al. Prognostic significance of left atrial enlargement in a general population: results of the PAMELA study. *Hypertension*. 2014; 64(6): 1205–1211, doi: [10.1161/HYPERTENSIONAHA.114.03975](https://doi.org/10.1161/HYPERTENSIONAHA.114.03975), indexed in Pubmed: [25201892](https://pubmed.ncbi.nlm.nih.gov/25201892/).
 125. Devereux RB, Wachtell K, Gerds E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. *JAMA*. 2004; 292(19): 2350–2356, doi: [10.1001/jama.292.19.2350](https://doi.org/10.1001/jama.292.19.2350), indexed in Pubmed: [15547162](https://pubmed.ncbi.nlm.nih.gov/15547162/).
 126. de Simone G, Izzo R, Aurigemma GP, et al. Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities. *J Hypertens*. 2015; 33(4): 745–754; discussion 754, doi: [10.1097/HJH.0000000000000477](https://doi.org/10.1097/HJH.0000000000000477), indexed in Pubmed: [25915879](https://pubmed.ncbi.nlm.nih.gov/25915879/).
 127. Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension: a report from

- the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). *Eur Heart J Cardiovasc Imaging*. 2015; 16(6): 577–605, doi: [10.1093/ehjci/jev076](https://doi.org/10.1093/ehjci/jev076), indexed in Pubmed: [25995329](https://pubmed.ncbi.nlm.nih.gov/25995329/).
128. Gerds E, Wachtell K, Omvik P, et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. *Hypertension*. 2007; 49(2): 311–316, doi: [10.1161/01.HYP.0000254322.96189.85](https://doi.org/10.1161/01.HYP.0000254322.96189.85), indexed in Pubmed: [17178978](https://pubmed.ncbi.nlm.nih.gov/17178978/).
 129. Muiesan ML, Salvetti M, Monteduro C, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. *Hypertension*. 2004; 43(4): 731–738, doi: [10.1161/01.HYP.0000121223.44837.de](https://doi.org/10.1161/01.HYP.0000121223.44837.de), indexed in Pubmed: [15007041](https://pubmed.ncbi.nlm.nih.gov/15007041/).
 130. Takeuchi M, Nishikage T, Mor-Avi V, et al. Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. *J Am Soc Echocardiogr*. 2008; 21(9): 1001–1005, doi: [10.1016/j.echo.2008.07.008](https://doi.org/10.1016/j.echo.2008.07.008), indexed in Pubmed: [18765176](https://pubmed.ncbi.nlm.nih.gov/18765176/).
 131. Stanton T, Jenkins C, Haluska BA, et al. Association of outcome with left ventricular parameters measured by two-dimensional and three-dimensional echocardiography in patients at high cardiovascular risk. *J Am Soc Echocardiogr*. 2014; 27(1): 65–73, doi: [10.1016/j.echo.2013.09.012](https://doi.org/10.1016/j.echo.2013.09.012), indexed in Pubmed: [24161481](https://pubmed.ncbi.nlm.nih.gov/24161481/).
 132. Codella NCF, Lee HY, Fieno DS, et al. Improved left ventricular mass quantification with partial voxel interpolation: in vivo and necropsy validation of a novel cardiac MRI segmentation algorithm. *Circ Cardiovasc Imaging*. 2012; 5(1): 137–146, doi: [10.1161/CIRCIMAGING.111.966754](https://doi.org/10.1161/CIRCIMAGING.111.966754), indexed in Pubmed: [22104165](https://pubmed.ncbi.nlm.nih.gov/22104165/).
 133. Weinsaft JW, Cham MD, Janik M, et al. Left ventricular papillary muscles and trabeculae are significant determinants of cardiac MRI volumetric measurements: effects on clinical standards in patients with advanced systolic dysfunction. *Int J Cardiol*. 2008; 126(3): 359–365, doi: [10.1016/j.ijcard.2007.04.179](https://doi.org/10.1016/j.ijcard.2007.04.179), indexed in Pubmed: [17698216](https://pubmed.ncbi.nlm.nih.gov/17698216/).
 134. Perrone-Filardi P, Coca A, Galderisi M, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). *Eur Heart J Cardiovasc Imaging*. 2017; 18(9): 945–960, doi: [10.1093/ehjci/jex094](https://doi.org/10.1093/ehjci/jex094), indexed in Pubmed: [28977550](https://pubmed.ncbi.nlm.nih.gov/28977550/).
 135. de Simone G, Kitzman DW, Chinali M, et al. Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. *Eur Heart J*. 2005; 26(10): 1039–1045, doi: [10.1093/eurheartj/ehi019](https://doi.org/10.1093/eurheartj/ehi019), indexed in Pubmed: [15618056](https://pubmed.ncbi.nlm.nih.gov/15618056/).
 136. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016; 37(27): 2129–2200, doi: [10.1093/eurheartj/ehw128](https://doi.org/10.1093/eurheartj/ehw128), indexed in Pubmed: [27206819](https://pubmed.ncbi.nlm.nih.gov/27206819/).
 137. Yaghi S, Moon YP, Mora-McLaughlin C, et al. Left atrial enlargement and stroke recurrence: the Northern Manhattan Stroke Study. *Stroke*. 2015; 46(6): 1488–1493, doi: [10.1161/STROKEAHA.115.008711](https://doi.org/10.1161/STROKEAHA.115.008711), indexed in Pubmed: [25908460](https://pubmed.ncbi.nlm.nih.gov/25908460/).
 138. Losi MA, Izzo R, De Marco M, et al. Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network. *Int J Cardiol*. 2015; 199: 290–295, doi: [10.1016/j.ijcard.2015.07.019](https://doi.org/10.1016/j.ijcard.2015.07.019), indexed in Pubmed: [26218588](https://pubmed.ncbi.nlm.nih.gov/26218588/).
 139. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. *J Am Coll Cardiol*. 2003; 42(7): 1206–1207, indexed in Pubmed: [14522481](https://pubmed.ncbi.nlm.nih.gov/14522481/).
 140. Kuznetsova T, Haddad F, Tikhonoff V, et al. European Project On Genes in Hypertension (EPOGH) Investigators. Impact and pitfalls of scaling of left ventricular and atrial structure in population-based studies. *J Hypertens*. 2016; 34(6): 1186–1194, doi: [10.1097/HJH.0000000000000922](https://doi.org/10.1097/HJH.0000000000000922), indexed in Pubmed: [27035735](https://pubmed.ncbi.nlm.nih.gov/27035735/).
 141. Evangelista A, Flachskampf FA, Erbel R, et al. European Association of Echocardiography, Document Reviewers. Echocardiography in aortic diseases: EAE recommendations for clinical practice. *Eur J Echocardiogr*. 2010; 11(8): 645–658, doi: [10.1093/ejecho-card/jeq056](https://doi.org/10.1093/ejecho-card/jeq056), indexed in Pubmed: [20823280](https://pubmed.ncbi.nlm.nih.gov/20823280/).
 142. Nambi V, Rubin J, Chambless LE, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. *J Am Coll Cardiol*. 2010; 55(15): 1600–1607, doi: [10.1016/j.jacc.2009.11.075](https://doi.org/10.1016/j.jacc.2009.11.075), indexed in Pubmed: [20378078](https://pubmed.ncbi.nlm.nih.gov/20378078/).
 143. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. *Atherosclerosis*. 2015; 241(2): 507–532, doi: [10.1016/j.atherosclerosis.2015.05.007](https://doi.org/10.1016/j.atherosclerosis.2015.05.007), indexed in Pubmed: [26117398](https://pubmed.ncbi.nlm.nih.gov/26117398/).
 144. Touboul PJ, Hennerici MG, Meairs S, et al. Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference. Mannheim intima-media thickness consensus. *Cerebrovasc Dis*. 2004; 18(4): 346–349, doi: [10.1159/000081812](https://doi.org/10.1159/000081812), indexed in Pubmed: [15523176](https://pubmed.ncbi.nlm.nih.gov/15523176/).
 145. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. *Atherosclerosis*. 2012; 220(1): 128–133, doi: [10.1016/j.atherosclerosis.2011.06.044](https://doi.org/10.1016/j.atherosclerosis.2011.06.044), indexed in Pubmed: [21764060](https://pubmed.ncbi.nlm.nih.gov/21764060/).
 146. Zanchetti A, Hennig M, Hollweck R, et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). *Circulation*. 2009; 120(12): 1084–1090, doi: [10.1161/CIRCULATIONAHA.108.773119](https://doi.org/10.1161/CIRCULATIONAHA.108.773119), indexed in Pubmed: [19738145](https://pubmed.ncbi.nlm.nih.gov/19738145/).
 147. Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima-media thickness and cardiovascular events. *N Engl J Med*. 2011; 365(3): 213–221, doi: [10.1056/NEJMoa1012592](https://doi.org/10.1056/NEJMoa1012592), indexed in Pubmed: [21774709](https://pubmed.ncbi.nlm.nih.gov/21774709/).
 148. Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J*. 2006; 27(21): 2588–2605, doi: [10.1093/eurheartj/ehl254](https://doi.org/10.1093/eurheartj/ehl254), indexed in Pubmed: [17000623](https://pubmed.ncbi.nlm.nih.gov/17000623/).
 149. Van Bortel LM, Laurent S, Boutouyrie P, et al. Artery Society, European Society of Hypertension Working Group on Vascular Structure and Function, European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J Hypertens*. 2012; 30(3): 445–448, doi: [10.1097/HJH.0b013e32834fa8b0](https://doi.org/10.1097/HJH.0b013e32834fa8b0), indexed in Pubmed: [22278144](https://pubmed.ncbi.nlm.nih.gov/22278144/).
 150. Reference Values for Arterial Stiffness Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. *Eur Heart J*. 2010; 31: 2338–2350.
 151. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. *J Am Coll Cardiol*. 2014; 63(7): 636–646, doi: [10.1016/j.jacc.2013.09.063](https://doi.org/10.1016/j.jacc.2013.09.063), indexed in Pubmed: [24239664](https://pubmed.ncbi.nlm.nih.gov/24239664/).
 152. Feringa HHH, Bax JJ, van Waning VH, et al. The long-term prognostic value of the resting and postexercise ankle-brachial index. *Arch Intern Med*. 2006; 166(5): 529–535, doi: [10.1001/archinte.166.5.529](https://doi.org/10.1001/archinte.166.5.529), indexed in Pubmed: [16534039](https://pubmed.ncbi.nlm.nih.gov/16534039/).
 153. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. *JAMA*. 2008; 300: 197–208, doi: [10.1001/jama.300.2.197](https://doi.org/10.1001/jama.300.2.197).
 154. De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. *Prog Cardiovasc Dis*. 2008; 50(4): 238–263, doi: [10.1016/j.pcad.2007.08.001](https://doi.org/10.1016/j.pcad.2007.08.001), indexed in Pubmed: [18156004](https://pubmed.ncbi.nlm.nih.gov/18156004/).
 155. Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. *Kidney Int*. 2017; 91(3): 683–690, doi: [10.1016/j.kint.2016.09.038](https://doi.org/10.1016/j.kint.2016.09.038), indexed in Pubmed: [27927602](https://pubmed.ncbi.nlm.nih.gov/27927602/).

156. Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. *BMJ*. 2017; 356: j791, indexed in Pubmed: [28279964](#).
157. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009; 150(9): 604–612, indexed in Pubmed: [19414839](#).
158. Gerstein HC, Mann JF, Yi Q, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA*. 2001; 286(4): 421–426, indexed in Pubmed: [11466120](#).
159. CKD Work Group, Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int*. 2013; 13(3): 1–150.
160. McTaggart MP, Newall RG, Hirst JA, et al. Diagnostic accuracy of point-of-care tests for detecting albuminuria: a systematic review and meta-analysis. *Ann Intern Med*. 2014; 160(8): 550–557, doi: [10.7326/M13-2331](#), indexed in Pubmed: [24733196](#).
161. Breslin DJ, Gifford RW, Fairbairn JF, et al. Prognostic importance of ophthalmoscopic findings in essential hypertension. *JAMA*. 1966; 195(5): 335–338, indexed in Pubmed: [5951889](#).
162. FRANT R, GROEN J. Prognosis of vascular hypertension; a 9 year follow-up study of 418 cases. *Arch Intern Med (Chic)*. 1950; 85(5): 727–750, indexed in Pubmed: [15414008](#).
163. Sairenchi T, Iso H, Yamagishi K, et al. Mild retinopathy is a risk factor for cardiovascular mortality in Japanese with and without hypertension: the Ibaraki Prefectural Health Study. *Circulation*. 2011; 124(23): 2502–2511, doi: [10.1161/CIRCULATIONAHA.111.049965](#), indexed in Pubmed: [22064594](#).
164. Dimmitt SB, West JN, Eames SM, et al. Usefulness of ophthalmoscopy in mild to moderate hypertension. *Lancet*. 1989; 1(8647): 1103–1106, indexed in Pubmed: [2566051](#).
165. Muiases ML, Salvetti M, Di Castelnuovo A, et al. Moli-sani Study Investigators. Obesity and ECG left ventricular hypertrophy. *J Hypertens*. 2017; 35(1): 162–169, doi: [10.1097/HJH.0000000000001121](#), indexed in Pubmed: [27662187](#).
166. Longstreth WT, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. *Stroke*. 1996; 27(8): 1274–1282, indexed in Pubmed: [8711786](#).
167. Vermeer SE, Longstreth WT, Koudstaal PJ. Silent brain infarcts: a systematic review. *Lancet Neurol*. 2007; 6(7): 611–619, doi: [10.1016/S1474-4422\(07\)70170-9](#), indexed in Pubmed: [17582361](#).
168. Iadecola C, Yaffe K, Biller J, et al. American Heart Association Council on Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. *Hypertension*. 2016; 68(6): e67–e94, doi: [10.1161/HYP.0000000000000053](#), indexed in Pubmed: [27977393](#).
169. Kearney-Schwartz A, Rossignol P, Bracard S, et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. *Stroke*. 2009; 40(4): 1229–1236, doi: [10.1161/STROKEAHA.108.532853](#), indexed in Pubmed: [19246701](#).
170. Tsoi KKF, Chan JYC, Hirai HW, et al. Cognitive Tests to Detect Dementia: A Systematic Review and Meta-analysis. *JAMA Intern Med*. 2015; 175(9): 1450–1458, doi: [10.1001/jamainternmed.2015.2152](#), indexed in Pubmed: [26052687](#).
171. Kato Y, Suzuki S, Uejima T, et al. Variable prognostic value of blood pressure response to exercise. *J Cardiol*. 2018; 71(1): 31–35, doi: [10.1016/j.jcc.2017.07.004](#), indexed in Pubmed: [28802909](#).
172. Bang CN, Devereux RB, Okin PM. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction — A LIFE review. *J Electrocardiol*. 2014; 47(5): 630–635, doi: [10.1016/j.jelectrocard.2014.07.003](#), indexed in Pubmed: [25052475](#).
173. Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. *Hypertension*. 2009; 54(5): 1084–1091, doi: [10.1161/HYPERTENSIONAHA.109.136655](#), indexed in Pubmed: [19770405](#).
174. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. *Hypertension*. 2005; 45(2): 198–202, doi: [10.1161/01.HYP.0000154082.72286.2a](#), indexed in Pubmed: [15655123](#).
175. Bakris GL, Sarafidis PA, Weir MR, et al. ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. *Lancet*. 2010; 375(9721): 1173–1181, doi: [10.1016/S0140-6736\(09\)62100-0](#), indexed in Pubmed: [20170948](#).
176. Haller H, Ito S, Izzo J, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. *N Engl J Med*. 2011; 364(10): 907–917, doi: [10.1056/nejmoa1007994](#).
177. Holtkamp FA, de Zeeuw D, de Graeff PA, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. *Eur Heart J*. 2011; 32(12): 1493–1499, doi: [10.1093/eurheartj/ehr017](#), indexed in Pubmed: [21421598](#).
178. Inker LA, Mondal H, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. *Am J Kidney Dis*. 2014; 64(1): 74–85, doi: [10.1053/j.ajkd.2014.02.020](#), indexed in Pubmed: [24787763](#).
179. de Galan BE, Perkovic V, Ninomiya T, et al. ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. *J Am Soc Nephrol*. 2009; 20(4): 883–892, doi: [10.1681/ASN.2008070667](#), indexed in Pubmed: [19225038](#).
180. Ninomiya T, Perkovic V, de Galan BE, et al. ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *J Am Soc Nephrol*. 2009; 20(8): 1813–1821, doi: [10.1681/ASN.2008121270](#), indexed in Pubmed: [19443635](#).
181. Chowdhury EK, Langham RG, Ademi Z, et al. Second Australian National Blood Pressure Study Management Committee. Rate of change in renal function and mortality in elderly treated hypertensive patients. *Clin J Am Soc Nephrol*. 2015; 10(7): 1154–1161, doi: [10.2215/CJN.07370714](#), indexed in Pubmed: [25901093](#).
182. Matsushita K, Selvin E, Bash LD, et al. Change in estimated GFR associates with coronary heart disease and mortality. *J Am Soc Nephrol*. 2009; 20(12): 2617–2624, doi: [10.1681/ASN.2009010025](#), indexed in Pubmed: [19892932](#).
183. Costanzo P, Perrone-Filardi P, Vassallo E, et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. *J Am Coll Cardiol*. 2010; 56(24): 2006–2020, doi: [10.1016/j.jacc.2010.05.059](#), indexed in Pubmed: [21126642](#).
184. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. *Stroke*. 2006; 37(7): 1933–1940, doi: [10.1161/01.STR.0000227223.90239.13](#), indexed in Pubmed: [16763185](#).
185. Izzo R, Losi MA, Stabile E, et al. Development of Left Ventricular Hypertrophy in Treated Hypertensive Outpatients: The Campania Salute Network. *Hypertension*. 2017; 69(1): 136–142, doi: [10.1161/HYPERTENSIONAHA.116.08158](#), indexed in Pubmed: [27895192](#).
186. Schmieler RE, Mann JFE, Schumacher H, et al. ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. *J Am Soc Nephrol*. 2011; 22(7): 1353–1364, doi: [10.1681/ASN.2010091001](#), indexed in Pubmed: [21719791](#).
187. Verdecchia P, Dagenais G, Healey J, et al. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial-Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects

- with cardiovascular Disease studies. *J Hypertens.* 2012; 30(5): 1004–1014, doi: [10.1097/HJH.0b013e3283522a51](https://doi.org/10.1097/HJH.0b013e3283522a51), indexed in Pubmed: [22495138](https://pubmed.ncbi.nlm.nih.gov/22495138/).
188. Criqui MH, Ninomiya JK, Wingard DL, et al. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. *J Am Coll Cardiol.* 2008; 52(21): 1736–1742, doi: [10.1016/j.jacc.2008.07.060](https://doi.org/10.1016/j.jacc.2008.07.060), indexed in Pubmed: [19007695](https://pubmed.ncbi.nlm.nih.gov/19007695/).
 189. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. *Hypertension.* 2001; 37(5): 1236–1241, indexed in Pubmed: [11358934](https://pubmed.ncbi.nlm.nih.gov/11358934/).
 190. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J.* 2017; 39: 763–816.
 191. Fagard R, Brguljan J, Staessen J, et al. Heritability of conventional and ambulatory blood pressures. A study in twins. *Hypertension.* 1995; 26(6, Pt 1): 919–924, indexed in Pubmed: [7490149](https://pubmed.ncbi.nlm.nih.gov/7490149/).
 192. Luft FC. Twins in cardiovascular genetic research. *Hypertension.* 2001; 37(2 Pt 2): 350–356, indexed in Pubmed: [11230299](https://pubmed.ncbi.nlm.nih.gov/11230299/).
 193. Warren HR, Evangelou E, Cabrera CP, et al. International Consortium of Blood Pressure (ICBP) 1000G Analyses, The CHD Exome+ Consortium, The ExomeBP Consortium, The T2D-GENES Consortium, The GoT2DGenes Consortium, The Cohorts for Heart and Ageing Research in Genome Epidemiology (CHARGE) BP Exome Consortium, The International Genomics of Blood Pressure (iGEN-BP) Consortium, UK Biobank CardioMetabolic Consortium BP working group. Corrigendum: Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet.* 2017; 49(10): 403–415.
 194. Burrello J, Monticone S, Buffolo F, et al. Is There a Role for Genomics in the Management of Hypertension? *Int J Mol Sci.* 2017; 18(6), doi: [10.3390/ijms18061131](https://doi.org/10.3390/ijms18061131), indexed in Pubmed: [28587112](https://pubmed.ncbi.nlm.nih.gov/28587112/).
 195. Dominiczak A, Delles C, Padmanabhan S. Genomics and precision medicine for clinicians and scientists in hypertension. *Hypertension.* 2017; 69: e10–e13.
 196. Zennaro MC, Boukroun S, Fernandes-Rosa F. An update on novel mechanisms of primary aldosteronism. *J Endocrinol.* 2015; 224(2): R63–R77, doi: [10.1530/JOE-14-0597](https://doi.org/10.1530/JOE-14-0597), indexed in Pubmed: [25424518](https://pubmed.ncbi.nlm.nih.gov/25424518/).
 197. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and pheochromocytoma: from genetics to personalized medicine. *Nat Rev Endocrinol.* 2015; 11(2): 101–111, doi: [10.1038/nrendo.2014.188](https://doi.org/10.1038/nrendo.2014.188), indexed in Pubmed: [25385035](https://pubmed.ncbi.nlm.nih.gov/25385035/).
 198. Lenders JWM, Duh QY, Eisenhofer G, et al. Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2014; 99(6): 1915–1942, doi: [10.1210/jc.2014-1498](https://doi.org/10.1210/jc.2014-1498), indexed in Pubmed: [24893135](https://pubmed.ncbi.nlm.nih.gov/24893135/).
 199. Toledo RA, Burnichon N, Cascon A, et al. NGS in PPGL (NGSnP-PGL) Study Group. Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary pheochromocytomas and paragangliomas. *Nat Rev Endocrinol.* 2017; 13(4): 233–247, doi: [10.1038/nrendo.2016.185](https://doi.org/10.1038/nrendo.2016.185), indexed in Pubmed: [27857127](https://pubmed.ncbi.nlm.nih.gov/27857127/).
 200. Plouin PF, Amar L, Dekkers OM, et al. Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a pheochromocytoma or a paraganglioma. *Eur J Endocrinol.* 2016; 174: G1–G10.
 201. Brunström M, Carlberg Bo. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. *JAMA Intern Med.* 2018; 178(1): 28–36, doi: [10.1001/jamainternmed.2017.6015](https://doi.org/10.1001/jamainternmed.2017.6015), indexed in Pubmed: [29131895](https://pubmed.ncbi.nlm.nih.gov/29131895/).
 202. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. *Br Med Bull.* 1994; 50(2): 272–298, indexed in Pubmed: [8205459](https://pubmed.ncbi.nlm.nih.gov/8205459/).
 203. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. *CMAJ.* 2013; 185(11): 949–957, doi: [10.1503/cmaj.121468](https://doi.org/10.1503/cmaj.121468), indexed in Pubmed: [23798459](https://pubmed.ncbi.nlm.nih.gov/23798459/).
 204. Chalmers J, Woodward M, Borghi C, et al. Strategies to meet the need for long-term data. *J Hypertens.* 2016; 34(8): 1473–1479, doi: [10.1097/HJH.0000000000000987](https://doi.org/10.1097/HJH.0000000000000987), indexed in Pubmed: [27270189](https://pubmed.ncbi.nlm.nih.gov/27270189/).
 205. Cirillo M, Terradura-Vagnarelli O, Mancini M, et al. Cohort profile: The Gubbio Population Study. *Int J Epidemiol.* 2014; 43(3): 713–720, doi: [10.1093/ije/dyt025](https://doi.org/10.1093/ije/dyt025), indexed in Pubmed: [23543599](https://pubmed.ncbi.nlm.nih.gov/23543599/).
 206. Sytkowski PA, D’Agostino RB, Belanger AJ, et al. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. *Circulation.* 1996; 93(4): 697–703, indexed in Pubmed: [8640998](https://pubmed.ncbi.nlm.nih.gov/8640998/).
 207. Zoungas S, Chalmers J, Neal B, et al. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. *N Engl J Med.* 2014; 371(15): 1392–1406, doi: [10.1056/nejmoa1407963](https://doi.org/10.1056/nejmoa1407963).
 208. Kjeldsen S, Feldman RD, Lisheng L, et al. Updated national and international hypertension guidelines: a review of current recommendations. *Drugs.* 2014; 74(17): 2033–2051, doi: [10.1007/s40265-014-0306-5](https://doi.org/10.1007/s40265-014-0306-5), indexed in Pubmed: [25315030](https://pubmed.ncbi.nlm.nih.gov/25315030/).
 209. Diao D, Wright JM, Cundiff DK, et al. Pharmacotherapy for mild hypertension. *Cochrane Database Syst Rev.* 2012(8): CD006742, doi: [10.1002/14651858.CD006742.pub2](https://doi.org/10.1002/14651858.CD006742.pub2), indexed in Pubmed: [22895954](https://pubmed.ncbi.nlm.nih.gov/22895954/).
 210. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. *J Hypertens.* 2009; 27(5): 923–934, doi: [10.1097/HJH.0b013e3283282aa6b5](https://doi.org/10.1097/HJH.0b013e3283282aa6b5), indexed in Pubmed: [19381107](https://pubmed.ncbi.nlm.nih.gov/19381107/).
 211. Sundström J, Arima H, Jackson R, et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. *Ann Intern Med.* 2015; 162(3): 184–191, doi: [10.7326/M14-0773](https://doi.org/10.7326/M14-0773), indexed in Pubmed: [25531552](https://pubmed.ncbi.nlm.nih.gov/25531552/).
 212. Lonn EM, Bosch J, López-Jaramillo P, et al. HOPE-3 Investigators. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. *N Engl J Med.* 2016; 374(21): 2009–2020, doi: [10.1056/NEJMoa1600175](https://doi.org/10.1056/NEJMoa1600175), indexed in Pubmed: [27041480](https://pubmed.ncbi.nlm.nih.gov/27041480/).
 213. Beckett N, Peters R, Leonetti G, et al. HYVET Study Group. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. *J Hypertens.* 2014; 32(7): 1478–87; discussion 1487, doi: [10.1097/HJH.0000000000000195](https://doi.org/10.1097/HJH.0000000000000195), indexed in Pubmed: [24984177](https://pubmed.ncbi.nlm.nih.gov/24984177/).
 214. Benetos A, Bulpitt CJ, Petrovic M, et al. An Expert Opinion from the European Society of Hypertension — European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects. *Hypertension.* 2016; 67(5): 820–825, doi: [10.1161/HYPERTENSIONAHA.115.07020](https://doi.org/10.1161/HYPERTENSIONAHA.115.07020), indexed in Pubmed: [26975708](https://pubmed.ncbi.nlm.nih.gov/26975708/).
 215. Williamson JD, Supiano MA, Applegate WB, et al. SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. *JAMA.* 2016; 315(24): 2673–2682, doi: [10.1001/jama.2016.7050](https://doi.org/10.1001/jama.2016.7050), indexed in Pubmed: [27195814](https://pubmed.ncbi.nlm.nih.gov/27195814/).
 216. Carlberg Bo. What do we know about the risks of stopping antihypertensive treatment? *J Hypertens.* 2014; 32(7): 1400–1401, doi: [10.1097/HJH.0000000000000200](https://doi.org/10.1097/HJH.0000000000000200), indexed in Pubmed: [24984175](https://pubmed.ncbi.nlm.nih.gov/24984175/).
 217. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. *J Hypertens.* 2017; 35: 2150–2160.
 218. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. *The Lancet.* 2014; 384(9943): 591–598, doi: [10.1016/s0140-6736\(14\)61212-5](https://doi.org/10.1016/s0140-6736(14)61212-5).
 219. Lim GB. Hypertension: Low sodium and DASH diet to lower blood pressure. *Nat Rev Cardiol.* 2018; 15(2): 68, doi: [10.1038/nrcardio.2017.214](https://doi.org/10.1038/nrcardio.2017.214), indexed in Pubmed: [29263447](https://pubmed.ncbi.nlm.nih.gov/29263447/).
 220. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med.* 2008; 358(18): 1887–1898, doi: [10.1056/NEJMoa0801369](https://doi.org/10.1056/NEJMoa0801369), indexed in Pubmed: [18378519](https://pubmed.ncbi.nlm.nih.gov/18378519/).
 221. Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens.* 2009; 27(11): 2121–2158, doi: [10.1097/HJH.0b013e328333146d](https://doi.org/10.1097/HJH.0b013e328333146d), indexed in Pubmed: [19838131](https://pubmed.ncbi.nlm.nih.gov/19838131/).
 222. Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from

- ONTARGET and TRANSCEND trials. *Lancet*. 2017; 389(10085): 2226–2237, doi: [10.1016/S0140-6736\(17\)30754-7](https://doi.org/10.1016/S0140-6736(17)30754-7), indexed in Pubmed: [28390695](https://pubmed.ncbi.nlm.nih.gov/28390695/).
223. Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. *Blood Press*. 2016; 25(2): 83–92, doi: [10.3109/08037051.2015.1106750](https://doi.org/10.3109/08037051.2015.1106750), indexed in Pubmed: [26511535](https://pubmed.ncbi.nlm.nih.gov/26511535/).
 224. Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. *Eur Heart J*. 2016; 37(12): 955–964, doi: [10.1093/eurheartj/ehv633](https://doi.org/10.1093/eurheartj/ehv633), indexed in Pubmed: [26590384](https://pubmed.ncbi.nlm.nih.gov/26590384/).
 225. Kjeldsen SE, Lund-Johansen P, Nilsson PM, et al. Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials. *Hypertension*. 2016; 67(5): 808–812, doi: [10.1161/HYPERTENSIONAHA.116.07257](https://doi.org/10.1161/HYPERTENSIONAHA.116.07257), indexed in Pubmed: [27001295](https://pubmed.ncbi.nlm.nih.gov/27001295/).
 226. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and meta-analyses of randomized trials. *J Hypertens*. 2016; 34(4): 613–622, doi: [10.1097/HJH.0000000000000881](https://doi.org/10.1097/HJH.0000000000000881), indexed in Pubmed: [26848994](https://pubmed.ncbi.nlm.nih.gov/26848994/).
 227. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events — meta-analyses of randomized trials. *J Hypertens*. 2016; 34(8): 1451–1463, doi: [10.1097/HJH.0000000000000972](https://doi.org/10.1097/HJH.0000000000000972), indexed in Pubmed: [27228434](https://pubmed.ncbi.nlm.nih.gov/27228434/).
 228. Tarnow L, Rossing P, Jensen C, et al. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. *Diabetes Care*. 2000; 23(12): 1725–1730, doi: [10.2337/diacare.23.12.1725](https://doi.org/10.2337/diacare.23.12.1725).
 229. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *The Lancet*. 2007; 370(9590): 829–840, doi: [10.1016/s0140-6736\(07\)61303-8](https://doi.org/10.1016/s0140-6736(07)61303-8).
 230. Cushman WC, Evans GW, Byington RP, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010; 362(17): 1575–1585, doi: [10.1056/NEJMoa1001286](https://doi.org/10.1056/NEJMoa1001286), indexed in Pubmed: [20228401](https://pubmed.ncbi.nlm.nih.gov/20228401/).
 231. Brunström M, Carlberg Bo. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. *BMJ*. 2016; 352: i717, indexed in Pubmed: [26920333](https://pubmed.ncbi.nlm.nih.gov/26920333/).
 232. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. *Circulation*. 2011; 123(24): 2799–810, 9 p following 810, doi: [10.1161/CIRCULATIONAHA.110.016337](https://doi.org/10.1161/CIRCULATIONAHA.110.016337), indexed in Pubmed: [21632497](https://pubmed.ncbi.nlm.nih.gov/21632497/).
 233. Black HR, Elliott WJ, Grandits G, et al. CONVINCe Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. *JAMA*. 2003; 289(16): 2073–2082, doi: [10.1001/jama.289.16.2073](https://doi.org/10.1001/jama.289.16.2073), indexed in Pubmed: [12709465](https://pubmed.ncbi.nlm.nih.gov/12709465/).
 234. Steptoe A, Breeze E, Banks J, et al. Cohort profile: the English longitudinal study of ageing. *Int J Epidemiol*. 2013; 42(6): 1640–1648, doi: [10.1093/ije/dys168](https://doi.org/10.1093/ije/dys168), indexed in Pubmed: [23143611](https://pubmed.ncbi.nlm.nih.gov/23143611/).
 235. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10. Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. *J Hypertens*. 2017; 35(5): 922–944, doi: [10.1097/HJH.0000000000001276](https://doi.org/10.1097/HJH.0000000000001276), indexed in Pubmed: [28141660](https://pubmed.ncbi.nlm.nih.gov/28141660/).
 236. Margolis KL, O'Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. *Diabetes Care*. 2014; 37(6): 1721–1728, doi: [10.2337/dc13-2334](https://doi.org/10.2337/dc13-2334), indexed in Pubmed: [24595629](https://pubmed.ncbi.nlm.nih.gov/24595629/).
 237. Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet*. 1998; 351(9118): 1755–1762, indexed in Pubmed: [9635947](https://pubmed.ncbi.nlm.nih.gov/9635947/).
 238. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *UK Prospective Diabetes Study Group*. *BMJ*. 1998; 317(7160): 703–713, indexed in Pubmed: [9732337](https://pubmed.ncbi.nlm.nih.gov/9732337/).
 239. Mancia G, Messerli FH, Franklin SS, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. *Hypertension*. 2007; 50(2): 299–305, doi: [10.1161/HYPERTENSIONAHA.107.090290](https://doi.org/10.1161/HYPERTENSIONAHA.107.090290), indexed in Pubmed: [17606861](https://pubmed.ncbi.nlm.nih.gov/17606861/).
 240. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet*. 2010; 375(9718): 895–905, doi: [10.1016/S0140-6736\(10\)60308-X](https://doi.org/10.1016/S0140-6736(10)60308-X), indexed in Pubmed: [20226988](https://pubmed.ncbi.nlm.nih.gov/20226988/).
 241. Mancia G, Schumacher H, Böhm M, et al. Relative and combined prognostic importance of on-treatment mean and visit-to-visit blood pressure variability in ONTARGET and TRANSCEND patients. *Hypertension*. 2017; 70(5): 938–948, doi: [10.1161/HYPERTENSIONAHA.117.09714](https://doi.org/10.1161/HYPERTENSIONAHA.117.09714), indexed in Pubmed: [28974567](https://pubmed.ncbi.nlm.nih.gov/28974567/).
 242. Parati G, Ochoa JE, Bilo G, et al. SPRINT Blood Pressure: Sprinting Back to Smirk's Basal Blood Pressure? *Hypertension*. 2017; 69(1): 15–19, doi: [10.1161/HYPERTENSIONAHA.116.08216](https://doi.org/10.1161/HYPERTENSIONAHA.116.08216), indexed in Pubmed: [27849568](https://pubmed.ncbi.nlm.nih.gov/27849568/).
 243. Mancia G, Parati G, Bilo G, et al. Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). *Hypertension*. 2012; 60(6): 1400–1406, doi: [10.1161/HYPERTENSIONAHA.112.199562](https://doi.org/10.1161/HYPERTENSIONAHA.112.199562), indexed in Pubmed: [23071122](https://pubmed.ncbi.nlm.nih.gov/23071122/).
 244. Odden MC, McClure LA, Sawaya BP, et al. Achieved blood pressure and outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. *Hypertension*. 2016; 67(1): 63–69, doi: [10.1161/HYPERTENSIONAHA.115.06480](https://doi.org/10.1161/HYPERTENSIONAHA.115.06480), indexed in Pubmed: [26553236](https://pubmed.ncbi.nlm.nih.gov/26553236/).
 245. Stevens V. Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II. *Annals of Internal Medicine*. 2001; 134(1): 1, doi: [10.7326/0003-4819-134-1-200101020-00007](https://doi.org/10.7326/0003-4819-134-1-200101020-00007).
 246. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. *JAMA*. 1998; 279(11): 839–846, indexed in Pubmed: [9515998](https://pubmed.ncbi.nlm.nih.gov/9515998/).
 247. Elliott P, Stamler J, Nichols R, et al. Intersalt Cooperative Research Group. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. *BMJ*. 1996; 312(7041): 1249–1253, indexed in Pubmed: [8634612](https://pubmed.ncbi.nlm.nih.gov/8634612/).
 248. He FJ, Li J, Macgregor GA, et al. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. *BMJ*. 2013; 346(4): f1325, indexed in Pubmed: [23558162](https://pubmed.ncbi.nlm.nih.gov/23558162/).
 249. Suckling RJ, He FJ, Markandu ND, et al. Modest salt reduction lowers blood pressure and albumin excretion in impaired glucose tolerance and type 2 diabetes mellitus: a randomized double-blind trial. *Hypertension*. 2016; 67(6): 1189–1195, doi: [10.1161/HYPERTENSIONAHA.115.06637](https://doi.org/10.1161/HYPERTENSIONAHA.115.06637), indexed in Pubmed: [27160199](https://pubmed.ncbi.nlm.nih.gov/27160199/).
 250. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. (Cochrane Review). *Am J Hypertens*. 2012; 25: 1–15.
 251. He FJ, MacGregor GA. How far should salt intake be reduced? *Hypertension*. 2003; 42(6): 1093–1099, doi: [10.1161/01.HYP.0000102864.05174.E8](https://doi.org/10.1161/01.HYP.0000102864.05174.E8), indexed in Pubmed: [14610100](https://pubmed.ncbi.nlm.nih.gov/14610100/).
 252. Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reductions on future cardiovascular disease. *N Engl J Med*. 2010; 362(7): 590–599, doi: [10.1056/NEJMoa0907355](https://doi.org/10.1056/NEJMoa0907355), indexed in Pubmed: [20089957](https://pubmed.ncbi.nlm.nih.gov/20089957/).
 253. He FJ, Burnier M, Macgregor GA. Nutrition in cardiovascular disease: salt in hypertension and heart failure. *Eur Heart J*. 2011; 32(24): 3073–3080, doi: [10.1093/eurheartj/ehr194](https://doi.org/10.1093/eurheartj/ehr194), indexed in Pubmed: [21705359](https://pubmed.ncbi.nlm.nih.gov/21705359/).
 254. He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. *Lancet*. 2011; 378(9789): 380–382, doi: [10.1016/S0140-6736\(11\)61174-4](https://doi.org/10.1016/S0140-6736(11)61174-4), indexed in Pubmed: [21803192](https://pubmed.ncbi.nlm.nih.gov/21803192/).

255. Taylor RS, Ashton KE, Moxham T, et al. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials. *Am J Hypertens.* 2011; 24(8): 843–853, doi: [10.1038/ajh.2011.115](https://doi.org/10.1038/ajh.2011.115), indexed in Pubmed: [21731062](https://pubmed.ncbi.nlm.nih.gov/21731062/).
256. Mente A, O'Donnell M, Rangarajan S, et al. PURE, EPIDREAM and ONTARGET/TRANSCEND Investigators. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. *Lancet.* 2016; 388(10043): 465–475, doi: [10.1016/S0140-6736\(16\)30467-6](https://doi.org/10.1016/S0140-6736(16)30467-6), indexed in Pubmed: [27216139](https://pubmed.ncbi.nlm.nih.gov/27216139/).
257. Binia A, Jaeger J, Hu Y, et al. Daily potassium intake and sodium-to-potassium ratio in the reduction of blood pressure: a meta-analysis of randomized controlled trials. *J Hypertens.* 2015; 33(8): 1509–1520, doi: [10.1097/HJH.0000000000000611](https://doi.org/10.1097/HJH.0000000000000611), indexed in Pubmed: [26039623](https://pubmed.ncbi.nlm.nih.gov/26039623/).
258. Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and meta-analyses. *BMJ.* 2013; 346: f1326, doi: [10.1136/bmj.f1326](https://doi.org/10.1136/bmj.f1326), indexed in Pubmed: [23558163](https://pubmed.ncbi.nlm.nih.gov/23558163/).
259. O'Donnell M, Mente A, Rangarajan S, et al. PURE Investigators. Urinary sodium and potassium excretion, mortality, and cardiovascular events. *N Engl J Med.* 2014; 371(7): 612–623, doi: [10.1056/NEJMoa1311889](https://doi.org/10.1056/NEJMoa1311889), indexed in Pubmed: [25119607](https://pubmed.ncbi.nlm.nih.gov/25119607/).
260. Cushman WC, Cutler JA, Hanna E, et al. Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. *Arch Intern Med.* 1998; 158(11): 1197–1207, indexed in Pubmed: [9625399](https://pubmed.ncbi.nlm.nih.gov/9625399/).
261. Holmes MV, Dale CE, Zuccolo L, et al. InterAct Consortium. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. *BMJ.* 2014; 349: g4164, doi: [10.1136/bmj.g4164](https://doi.org/10.1136/bmj.g4164), indexed in Pubmed: [25011450](https://pubmed.ncbi.nlm.nih.gov/25011450/).
262. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens.* 2006; 24(2): 215–233, doi: [10.1097/01.hjh.0000199800.72563.26](https://doi.org/10.1097/01.hjh.0000199800.72563.26), indexed in Pubmed: [16508562](https://pubmed.ncbi.nlm.nih.gov/16508562/).
263. Mente A, de Koning L, Shannon HS, et al. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med.* 2009; 169(7): 659–669, doi: [10.1001/archinternmed.2009.38](https://doi.org/10.1001/archinternmed.2009.38), indexed in Pubmed: [19364995](https://pubmed.ncbi.nlm.nih.gov/19364995/).
264. Sofi F, Abbate R, Gensini GF, et al. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. *Am J Clin Nutr.* 2010; 92(5): 1189–1196, doi: [10.3945/ajcn.2010.29673](https://doi.org/10.3945/ajcn.2010.29673), indexed in Pubmed: [20810976](https://pubmed.ncbi.nlm.nih.gov/20810976/).
265. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. *N Engl J Med.* 2013; 368(14): 1279–1290, doi: [10.1056/nejmoa1200303](https://doi.org/10.1056/nejmoa1200303).
266. Doménech M, Roman P, Lapetra J, et al. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: one-year randomized, clinical trial. *Hypertension.* 2014; 64(1): 69–76, doi: [10.1161/HYPERTENSIONAHA.113.03353](https://doi.org/10.1161/HYPERTENSIONAHA.113.03353), indexed in Pubmed: [24799608](https://pubmed.ncbi.nlm.nih.gov/24799608/).
267. Ding M, Bhupathiraju SN, Satija A, et al. Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. *Circulation.* 2014; 129(6): 643–659, doi: [10.1161/CIRCULATIONAHA.113.005925](https://doi.org/10.1161/CIRCULATIONAHA.113.005925), indexed in Pubmed: [24201300](https://pubmed.ncbi.nlm.nih.gov/24201300/).
268. Li G, Zhang Y, Thabane L, et al. Effect of green tea supplementation on blood pressure among overweight and obese adults: a systematic review and meta-analysis. *J Hypertens.* 2015; 33(2): 243–254, doi: [10.1097/HJH.0000000000000426](https://doi.org/10.1097/HJH.0000000000000426), indexed in Pubmed: [25479028](https://pubmed.ncbi.nlm.nih.gov/25479028/).
269. Greyling A, Ras RT, Zock PL, et al. The effect of black tea on blood pressure: a systematic review with meta-analysis of randomized controlled trials. *PLoS One.* 2014; 9(7): e103247, doi: [10.1371/journal.pone.0103247](https://doi.org/10.1371/journal.pone.0103247), indexed in Pubmed: [25079225](https://pubmed.ncbi.nlm.nih.gov/25079225/).
270. Hall JE, do Carmo JM, da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. *Circ Res.* 2015; 116(6): 991–1006, doi: [10.1161/CIRCRESAHA.116.305697](https://doi.org/10.1161/CIRCRESAHA.116.305697), indexed in Pubmed: [25767285](https://pubmed.ncbi.nlm.nih.gov/25767285/).
271. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension.* 2003; 42(5): 878–884, doi: [10.1161/01.HYP.0000094221.86888.AE](https://doi.org/10.1161/01.HYP.0000094221.86888.AE), indexed in Pubmed: [12975389](https://pubmed.ncbi.nlm.nih.gov/12975389/).
272. Whitlock G, Lewington S, Sherliker P, et al. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet.* 2009; 373(9669): 1083–1096, doi: [10.1016/S0140-6736\(09\)60318-4](https://doi.org/10.1016/S0140-6736(09)60318-4), indexed in Pubmed: [19299006](https://pubmed.ncbi.nlm.nih.gov/19299006/).
273. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA.* 2013; 309(1): 71–82, doi: [10.1001/jama.2012.113905](https://doi.org/10.1001/jama.2012.113905), indexed in Pubmed: [23280227](https://pubmed.ncbi.nlm.nih.gov/23280227/).
274. Angelantonio EDI, Bhupathiraju S, Wormser D, et al. Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *The Lancet.* 2016; 388(10046): 776–786, doi: [10.1016/s0140-6736\(16\)30175-1](https://doi.org/10.1016/s0140-6736(16)30175-1).
275. Jebb SA, Ahern AL, Olson AD, et al. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. *Lancet.* 2011; 378(9801): 1485–1492, doi: [10.1016/S0140-6736\(11\)61344-5](https://doi.org/10.1016/S0140-6736(11)61344-5), indexed in Pubmed: [21906798](https://pubmed.ncbi.nlm.nih.gov/21906798/).
276. Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. *J Hypertens.* 2012; 30(6): 1047–1055, doi: [10.1097/HJH.0b013e3283537347](https://doi.org/10.1097/HJH.0b013e3283537347), indexed in Pubmed: [22573071](https://pubmed.ncbi.nlm.nih.gov/22573071/).
277. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. *J Am Heart Assoc.* 2013; 2(1): e004473, doi: [10.1161/JAHA.112.004473](https://doi.org/10.1161/JAHA.112.004473), indexed in Pubmed: [23525435](https://pubmed.ncbi.nlm.nih.gov/23525435/).
278. Leitzmann MF, Park Y, Blair A, et al. Physical activity recommendations and decreased risk of mortality. *Arch Intern Med.* 2007; 167(22): 2453–2460, doi: [10.1001/archinte.167.22.2453](https://doi.org/10.1001/archinte.167.22.2453), indexed in Pubmed: [18071167](https://pubmed.ncbi.nlm.nih.gov/18071167/).
279. Rossi A, Dikareva A, Bacon SL, et al. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. *J Hypertens.* 2012; 30(7): 1277–1288, doi: [10.1097/HJH.0b013e3283544669](https://doi.org/10.1097/HJH.0b013e3283544669), indexed in Pubmed: [22573122](https://pubmed.ncbi.nlm.nih.gov/22573122/).
280. Mann SJ, James GD, Wang RS, et al. Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study. *JAMA.* 1991; 265(17): 2226–2228, indexed in Pubmed: [2013955](https://pubmed.ncbi.nlm.nih.gov/2013955/).
281. Koteva K, Wood D, De Bacquer D, et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *Eur J Prev Cardiol.* 2016; 23(6): 636–648, doi: [10.1177/2047487315569401](https://doi.org/10.1177/2047487315569401), indexed in Pubmed: [25687109](https://pubmed.ncbi.nlm.nih.gov/25687109/).
282. Yarlioglues M, Kaya MG, Ardic I, et al. Acute effects of passive smoking on blood pressure and heart rate in healthy females. *Blood Press Monit.* 2010; 15(5): 251–256, doi: [10.1097/MBP.0b013e32833e439f](https://doi.org/10.1097/MBP.0b013e32833e439f), indexed in Pubmed: [20729727](https://pubmed.ncbi.nlm.nih.gov/20729727/).
283. Groppelli A, Giorgi DM, Omboni S, et al. Persistent blood pressure increase induced by heavy smoking. *J Hypertens.* 1992; 10(5): 495–499, indexed in Pubmed: [1317911](https://pubmed.ncbi.nlm.nih.gov/1317911/).
284. Primatesta P, Falaschetti E, Gupta S, et al. Association between smoking and blood pressure: evidence from the health survey for England. *Hypertension.* 2001; 37(2): 187–193, indexed in Pubmed: [11230269](https://pubmed.ncbi.nlm.nih.gov/11230269/).
285. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. *BMJ.* 1994; 309(6959): 901–911, indexed in Pubmed: [7755693](https://pubmed.ncbi.nlm.nih.gov/7755693/).
286. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012; 380(9859): 2224–2260, doi: [10.1016/S0140-6736\(12\)61766-8](https://doi.org/10.1016/S0140-6736(12)61766-8), indexed in Pubmed: [23245609](https://pubmed.ncbi.nlm.nih.gov/23245609/).
287. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. *Cochrane Database Syst Rev.* 2013(5): CD000165, doi: [10.1002/14651858.CD000165.pub4](https://doi.org/10.1002/14651858.CD000165.pub4), indexed in Pubmed: [23728631](https://pubmed.ncbi.nlm.nih.gov/23728631/).
288. Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev.* 2013(5): CD009329, doi: [10.1002/14651858.CD009329.pub2](https://doi.org/10.1002/14651858.CD009329.pub2), indexed in Pubmed: [23728690](https://pubmed.ncbi.nlm.nih.gov/23728690/).

289. Stead LF, Koilpillai P, Fanshawe TR, et al. Combined pharmacotherapy and behavioural interventions for smoking cessation. *Cochrane Database Syst Rev*. 2016; 3: CD008286, doi: [10.1002/14651858.CD008286.pub3](https://doi.org/10.1002/14651858.CD008286.pub3), indexed in Pubmed: [27009521](https://pubmed.ncbi.nlm.nih.gov/27009521/).
290. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. *N Engl J Med*. 2010; 363(23): 2211–2219, doi: [10.1056/NEJMoa1000367](https://doi.org/10.1056/NEJMoa1000367), indexed in Pubmed: [21121834](https://pubmed.ncbi.nlm.nih.gov/21121834/).
291. Parving HH, Brenner BM, McMurray JVV, et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*. 2012; 367(23): 2204–2213, doi: [10.1056/NEJMoa1208799](https://doi.org/10.1056/NEJMoa1208799), indexed in Pubmed: [23121378](https://pubmed.ncbi.nlm.nih.gov/23121378/).
292. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. *J Hypertens*. 2015; 33(7): 1321–1341, doi: [10.1097/HJH.0000000000000614](https://doi.org/10.1097/HJH.0000000000000614), indexed in Pubmed: [26039526](https://pubmed.ncbi.nlm.nih.gov/26039526/).
293. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. *J Hypertens*. 2008; 26(4): 819–824, doi: [10.1097/HJH.0b013e3282f4edd7](https://doi.org/10.1097/HJH.0b013e3282f4edd7), indexed in Pubmed: [18327094](https://pubmed.ncbi.nlm.nih.gov/18327094/).
294. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. *J Hypertens*. 2016; 34(10): 1921–1932, doi: [10.1097/HJH.0000000000001052](https://doi.org/10.1097/HJH.0000000000001052), indexed in Pubmed: [27454050](https://pubmed.ncbi.nlm.nih.gov/27454050/).
295. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. *J Hypertens*. 2005; 23(12): 2113–2118, indexed in Pubmed: [16269950](https://pubmed.ncbi.nlm.nih.gov/16269950/).
296. Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. *J Hypertens*. 2008; 26(7): 1282–1289, doi: [10.1097/HJH.0b013e328306ebe2](https://doi.org/10.1097/HJH.0b013e328306ebe2), indexed in Pubmed: [18550998](https://pubmed.ncbi.nlm.nih.gov/18550998/).
297. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. *Circulation*. 2011; 123(15): 1611–1621, doi: [10.1161/CIRCULATIONAHA.110.983874](https://doi.org/10.1161/CIRCULATIONAHA.110.983874), indexed in Pubmed: [21464050](https://pubmed.ncbi.nlm.nih.gov/21464050/).
298. Fried LF, Emanuele N, Zhang JH, et al. VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. *N Engl J Med*. 2013; 369(20): 1892–1903, doi: [10.1056/NEJMoa1303154](https://doi.org/10.1056/NEJMoa1303154), indexed in Pubmed: [24206457](https://pubmed.ncbi.nlm.nih.gov/24206457/).
299. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008; 358(15): 1547–1559, doi: [10.1056/NEJMoa0801317](https://doi.org/10.1056/NEJMoa0801317), indexed in Pubmed: [18378520](https://pubmed.ncbi.nlm.nih.gov/18378520/).
300. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses. *J Hypertens*. 2015; 33(2): 195–211, doi: [10.1097/HJH.0000000000000447](https://doi.org/10.1097/HJH.0000000000000447), indexed in Pubmed: [25485720](https://pubmed.ncbi.nlm.nih.gov/25485720/).
301. Roush GC, Ernst ME, Kostis JB, et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. *Hypertension*. 2015; 65(5): 1041–1046, doi: [10.1161/HYPERTENSIONAHA.114.05021](https://doi.org/10.1161/HYPERTENSIONAHA.114.05021), indexed in Pubmed: [25733245](https://pubmed.ncbi.nlm.nih.gov/25733245/).
302. Olde Engberink RHG, Frenkel WJ, van den Bogaard B, et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. *Hypertension*. 2015; 65(5): 1033–1040, doi: [10.1161/HYPERTENSIONAHA.114.05122](https://doi.org/10.1161/HYPERTENSIONAHA.114.05122), indexed in Pubmed: [25733241](https://pubmed.ncbi.nlm.nih.gov/25733241/).
303. Zanchetti A, Mancia G. Strategies for antihypertensive treatment decisions: how to assess benefits? *J Hypertens*. 1997; 15(3): 215–216, indexed in Pubmed: [9468446](https://pubmed.ncbi.nlm.nih.gov/9468446/).
304. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. *Hypertension*. 2006; 48(2): 219–224, doi: [10.1161/01.HYP.0000231552.10054.aa](https://doi.org/10.1161/01.HYP.0000231552.10054.aa), indexed in Pubmed: [16801488](https://pubmed.ncbi.nlm.nih.gov/16801488/).
305. Brown MJ, Williams B, Morant SV, et al. British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. *Lancet Diabetes Endocrinol*. 2016; 4(2): 136–147, doi: [10.1016/S2213-8587\(15\)00377-0](https://doi.org/10.1016/S2213-8587(15)00377-0), indexed in Pubmed: [26489809](https://pubmed.ncbi.nlm.nih.gov/26489809/).
306. Dondo TB, Hall M, West RM, et al. Beta-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. *J Am Coll Cardiol*. 2017; 69(22): 2710–2720, doi: [10.1016/j.jacc.2017.03.578](https://doi.org/10.1016/j.jacc.2017.03.578), indexed in Pubmed: [28571635](https://pubmed.ncbi.nlm.nih.gov/28571635/).
307. Bakris GL, Fonseca V, Katholi RE, et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA*. 2004; 292(18): 2227–2236, doi: [10.1001/jama.292.18.2227](https://doi.org/10.1001/jama.292.18.2227), indexed in Pubmed: [15536109](https://pubmed.ncbi.nlm.nih.gov/15536109/).
308. Ayers K, Byrne LM, DeMatteo A, et al. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. *Hypertension*. 2012; 59(4): 893–898, doi: [10.1161/HYPERTENSIONAHA.111.189589](https://doi.org/10.1161/HYPERTENSIONAHA.111.189589), indexed in Pubmed: [22353614](https://pubmed.ncbi.nlm.nih.gov/22353614/).
309. Chapman N, Chang CL, Dahlöf B, et al. ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. *Circulation*. 2008; 118(1): 42–48, doi: [10.1161/CIRCULATIONAHA.107.737957](https://doi.org/10.1161/CIRCULATIONAHA.107.737957), indexed in Pubmed: [18559700](https://pubmed.ncbi.nlm.nih.gov/18559700/).
310. Williams B, MacDonald TM, Morant S, et al. British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet*. 2015; 386(10008): 2059–2068, doi: [10.1016/S0140-6736\(15\)00257-3](https://doi.org/10.1016/S0140-6736(15)00257-3), indexed in Pubmed: [26414968](https://pubmed.ncbi.nlm.nih.gov/26414968/).
311. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. *Arch Intern Med*. 2007; 167(2): 141–147, doi: [10.1001/archinte.167.2.141](https://doi.org/10.1001/archinte.167.2.141), indexed in Pubmed: [17242314](https://pubmed.ncbi.nlm.nih.gov/17242314/).
312. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. *J Hypertens*. 2011; 29(3): 610–618, doi: [10.1097/HJH.0b013e328342ca97](https://doi.org/10.1097/HJH.0b013e328342ca97), indexed in Pubmed: [21157368](https://pubmed.ncbi.nlm.nih.gov/21157368/).
313. Tiffe T, Wagner M, Rücker V, et al. Control of cardiovascular risk factors and its determinants in the general population- findings from the STAAB cohort study. *BMC Cardiovasc Disord*. 2017; 17(1): 276, doi: [10.1186/s12872-017-0708-x](https://doi.org/10.1186/s12872-017-0708-x), indexed in Pubmed: [29096615](https://pubmed.ncbi.nlm.nih.gov/29096615/).
314. Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. *Cardiol Clin*. 2010; 28(4): 609–622, doi: [10.1016/j.ccl.2010.08.002](https://doi.org/10.1016/j.ccl.2010.08.002), indexed in Pubmed: [20937445](https://pubmed.ncbi.nlm.nih.gov/20937445/).
315. Gupta P, Patel P, Strauch B, et al. Biochemical screening for non-adherence is associated with blood pressure reduction and improvement in adherence. *Hypertension*. 2017; 70(5): 1042–1048, doi: [10.1161/HYPERTENSIONAHA.117.09631](https://doi.org/10.1161/HYPERTENSIONAHA.117.09631), indexed in Pubmed: [28847892](https://pubmed.ncbi.nlm.nih.gov/28847892/).
316. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002; 288: 2981–2997.
317. Lindholm LH, Ibsen H, Dahlöf B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002; 359(9311): 995–1003, doi: [10.1016/S0140-6736\(02\)08089-3](https://doi.org/10.1016/S0140-6736(02)08089-3), indexed in Pubmed: [11937178](https://pubmed.ncbi.nlm.nih.gov/11937178/).
318. Dahlöf B, Sever P, Poulter N, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *The Lancet*. 2005; 366(9489): 895–906, doi: [10.1016/s0140-6736\(05\)67185-1](https://doi.org/10.1016/s0140-6736(05)67185-1).
319. McKavanagh P, Lusk L, Ball PA, et al. A comparison of cardiac computerized tomography and exercise stress electrocardiogram test for the investigation of stable chest pain: the clinical results of the CAPP randomized prospective trial. *Eur Heart J Cardiovasc Imaging*. 2015; 16(4): 441–448, doi: [10.1093/ehjci/jeu284](https://doi.org/10.1093/ehjci/jeu284), indexed in Pubmed: [25473041](https://pubmed.ncbi.nlm.nih.gov/25473041/).

320. Hedner T. Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. *Blood Press.* 1999; 8(5-6): 296–299, indexed in Pubmed: [10803490](#).
321. Elgendy IY, Bavry AA, Gong Y, et al. Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study. *Hypertension.* 2016; 68(5): 1110–1114, doi: [10.1161/HYPERTENSIONAHA.116.07854](#), indexed in Pubmed: [27620390](#).
322. Coope JR, Warrender TS, Coope J, et al. Randomised trial of treatment of hypertension in elderly patients in primary care. *Br Med J (Clin Res Ed).* 1986; 293(6555): 1145–1151, indexed in Pubmed: [3094811](#).
323. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA.* 1991; 265(24): 3255–3264, indexed in Pubmed: [2046107](#).
324. Dahlöf B, Anderson H, Ekblom T, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet.* 1991; 338(8778): 1281–1285, indexed in Pubmed: [1682683](#).
325. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and anti-hypertensive drugs. *J Hypertens.* 2006; 24(1): 3–10, indexed in Pubmed: [16331092](#).
326. Brown M, Palmer C, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *The Lancet.* 2000; 356(9227): 366–372, doi: [10.1016/s0140-6736\(00\)02527-7](#).
327. Bakris G, Briasoulis A, Dahlöf B, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med.* 2008; 359(23): 2417–2428, doi: [10.1056/NEJMoa0806182](#), indexed in Pubmed: [19052124](#).
328. Ogiwara T, Saruta T, Rakugi H, et al. COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. *Hypertens Res.* 2015; 38(1): 89–96, doi: [10.1038/hr.2014.144](#), indexed in Pubmed: [25253583](#).
329. Matsuzaki M, Ogiwara T, Umemoto S, et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. *J Hypertens.* 2011; 29(8): 1649–1659, doi: [10.1097/HJH.0b013e328348345d](#), indexed in Pubmed: [21610513](#).
330. Gayet JL, Lithell H, Hansson L, et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens.* 2003; 21(5): 875–886, doi: [10.1097/01.hjh.0000059028.82022.89](#), indexed in Pubmed: [12714861](#).
331. Liu L, Zhang Y, Liu G, et al. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. *J Hypertens.* 2005; 23(12): 2157–2172, indexed in Pubmed: [16269957](#).
332. Staessen JA, Fagard R, Thijs L, et al. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. *Lancet.* 1997; 350(9080): 757–764, indexed in Pubmed: [9297994](#).
333. Wang JG, Staessen JA, Liu L. Chinese Trial on Isolated Systolic Hypertension in the Elderly. *Arch Intern Med.* 2000; 160(2): 211–220, doi: [10.1001/archinte.160.2.211](#).
334. Hansson L, Lindholm LH, Ekblom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet.* 1999; 354(9192): 1751–1756, doi: [10.1016/s0140-6736\(99\)10327-1](#), indexed in Pubmed: [10577635](#).
335. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet.* 1999; 353(9153): 611–616, indexed in Pubmed: [10030325](#).
336. Zanchetti A, Hennig M, Baurecht H, et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. *J Hypertens.* 2007; 25(12): 2463–2470, doi: [10.1097/HJH.0b013e3282f063d5](#), indexed in Pubmed: [17984668](#).
337. Julius S, Weber MA, Kjeldsen SE, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet.* 2004; 363(9426): 2022–2031, doi: [10.1016/S0140-6736\(04\)16451-9](#), indexed in Pubmed: [15207952](#).
338. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *The Lancet.* 2001; 358(9287): 1033–1041, doi: [10.1016/s0140-6736\(01\)06178-5](#).
339. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet.* 2000; 356(9227): 359–365, doi: [10.1016/s0140-6736\(00\)02526-5](#), indexed in Pubmed: [10972367](#).
340. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *JAMA.* 2003; 290(21): 2805–2816, doi: [10.1001/jama.290.21.2805](#), indexed in Pubmed: [14657064](#).
341. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med.* 2009; 122(3): 290–300, doi: [10.1016/j.amjmed.2008.09.038](#), indexed in Pubmed: [19272490](#).
342. MacDonald TM, Williams B, Webb DJ, et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY). Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. *J Am Heart Assoc.* 2017; 6(11), doi: [10.1161/JAHA.117.006986](#), indexed in Pubmed: [29151036](#).
343. Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. *N Engl J Med.* 2016; 374(21): 2032–2043, doi: [10.1056/nejmoa1600177](#).
344. Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. *BMJ.* 2015; 350: h158, indexed in Pubmed: [25655523](#).
345. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. *Hypertension.* 2012; 59(6): 1124–1131, doi: [10.1161/HYPERTENSIONAHA.112.194167](#), indexed in Pubmed: [22566499](#).
346. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. *J Hypertens.* 2010; 28(7): 1584–1590, doi: [10.1097/HJH.0b013e328339f9fa](#), indexed in Pubmed: [20543716](#).
347. Conn VS, Ruppert TM, Chase JAD, et al. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. *Curr Hypertens Rep.* 2015; 17(12): 94, doi: [10.1007/s11906-015-0606-5](#), indexed in Pubmed: [26560139](#).
348. Mancia G, Rea F, Cuspidi C, et al. Blood pressure control in hypertension. Pros and cons of available treatment strategies. *J Hypertens.* 2017; 35(2): 225–233, doi: [10.1097/HJH.0000000000001181](#), indexed in Pubmed: [27898507](#).
349. Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. *J Clin Hypertens (Greenwich).* 2011; 13(6): 404–412, doi: [10.1111/j.1751-7176.2011.00437.x](#), indexed in Pubmed: [21649839](#).
350. Volpe M, Christian Rump L, Ammentorp B, et al. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. *Clin Drug Investig.* 2012; 32(10): 649–664, doi: [10.2165/11636320-00000000-00000](#), indexed in Pubmed: [22909147](#).

351. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. *Hypertension*. 2010; 55(2): 399–407, doi: [10.1161/HYPERTENSIONAHA.109.139816](https://doi.org/10.1161/HYPERTENSIONAHA.109.139816), indexed in Pubmed: [20026768](https://pubmed.ncbi.nlm.nih.gov/20026768/).
352. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. *J Hypertens*. 2013; 31(4): 766–774, doi: [10.1097/HJH.0b013e32835e2286](https://doi.org/10.1097/HJH.0b013e32835e2286), indexed in Pubmed: [23337469](https://pubmed.ncbi.nlm.nih.gov/23337469/).
353. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2018; 39: 119–177.
354. Gupta P, Patel P, Horne R, et al. How to screen for non-adherence to antihypertensive therapy. *Curr Hypertens Rep*. 2016; 18(12): 89, doi: [10.1007/s11906-016-0697-7](https://doi.org/10.1007/s11906-016-0697-7), indexed in Pubmed: [27889904](https://pubmed.ncbi.nlm.nih.gov/27889904/).
355. Coca A, Agabiti-Rosei E, Cifkova R, et al. The polypill in cardiovascular prevention: evidence, limitations and perspective — position paper of the European Society of Hypertension. *J Hypertens*. 2017; 35(8): 1546–1553, doi: [10.1097/HJH.0000000000001390](https://doi.org/10.1097/HJH.0000000000001390), indexed in Pubmed: [28448291](https://pubmed.ncbi.nlm.nih.gov/28448291/).
356. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. *J Am Coll Cardiol*. 2014; 64(20): 2071–2082, doi: [10.1016/j.jacc.2014.08.021](https://doi.org/10.1016/j.jacc.2014.08.021), indexed in Pubmed: [25193393](https://pubmed.ncbi.nlm.nih.gov/25193393/).
357. Williams B, MacDonald TM, Morant SV, et al. British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. *Lancet Diabetes Endocrinol*. 2018; 6(6): 464–475, doi: [10.1016/S2213-8587\(18\)30071-8](https://doi.org/10.1016/S2213-8587(18)30071-8), indexed in Pubmed: [29655877](https://pubmed.ncbi.nlm.nih.gov/29655877/).
358. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. *J Am Coll Cardiol*. 2011; 58(7): 765–773, doi: [10.1016/j.jacc.2011.06.008](https://doi.org/10.1016/j.jacc.2011.06.008), indexed in Pubmed: [21816315](https://pubmed.ncbi.nlm.nih.gov/21816315/).
359. Wachter R, Halbach M, Bakris GL, et al. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. *J Am Soc Hypertens*. 2017; 11(2): 81–91, doi: [10.1016/j.jash.2016.12.003](https://doi.org/10.1016/j.jash.2016.12.003), indexed in Pubmed: [28065708](https://pubmed.ncbi.nlm.nih.gov/28065708/).
360. Spiering W, Williams B, Van der Heyden J, et al. CALM-FIM_EUR investigators. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. *Lancet*. 2017; 390(10113): 2655–2661, doi: [10.1016/S0140-6736\(17\)32337-1](https://doi.org/10.1016/S0140-6736(17)32337-1), indexed in Pubmed: [28870716](https://pubmed.ncbi.nlm.nih.gov/28870716/).
361. DiBona GF. Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. *Am J Physiol Regul Integr Comp Physiol*. 2005; 289(3): R633–R641, doi: [10.1152/ajpregu.00258.2005](https://doi.org/10.1152/ajpregu.00258.2005), indexed in Pubmed: [16105818](https://pubmed.ncbi.nlm.nih.gov/16105818/).
362. Esler M. Sympathetic nervous system moves toward center stage in cardiovascular medicine: from Thomas Willis to resistant hypertension. *Hypertension*. 2014; 63(3): e25–e32, doi: [10.1161/HYPERTENSIONAHA.113.02439](https://doi.org/10.1161/HYPERTENSIONAHA.113.02439), indexed in Pubmed: [24420544](https://pubmed.ncbi.nlm.nih.gov/24420544/).
363. Mahfoud F, Böhm M, Azizi M, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. *Eur Heart J*. 2015; 36(33): 2219–2227, doi: [10.1093/eurheartj/ehv192](https://doi.org/10.1093/eurheartj/ehv192), indexed in Pubmed: [25990344](https://pubmed.ncbi.nlm.nih.gov/25990344/).
364. Böhm M, Mahfoud F, Ukena C, et al. GSR Investigators. First report of the Global SYMPPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. *Hypertension*. 2015; 65(4): 766–774, doi: [10.1161/HYPERTENSIONAHA.114.05010](https://doi.org/10.1161/HYPERTENSIONAHA.114.05010), indexed in Pubmed: [25691618](https://pubmed.ncbi.nlm.nih.gov/25691618/).
365. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. *Lancet*. 2014; 383(9917): 622–629, doi: [10.1016/S0140-6736\(13\)62192-3](https://doi.org/10.1016/S0140-6736(13)62192-3), indexed in Pubmed: [24210779](https://pubmed.ncbi.nlm.nih.gov/24210779/).
366. Townsend RR, Mahfoud F, Kandzari DE, et al. SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. *Lancet*. 2017; 390(10108): 2160–2170, doi: [10.1016/S0140-6736\(17\)32281-X](https://doi.org/10.1016/S0140-6736(17)32281-X), indexed in Pubmed: [28859944](https://pubmed.ncbi.nlm.nih.gov/28859944/).
367. Bhatt DL, Kandzari DE, O'Neill WW, et al. SYMPPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. *N Engl J Med*. 2014; 370(15): 1393–1401, doi: [10.1056/NEJMoa1402670](https://doi.org/10.1056/NEJMoa1402670), indexed in Pubmed: [24678939](https://pubmed.ncbi.nlm.nih.gov/24678939/).
368. Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. *J Hypertens*. 2016; 34(8): 1639–1647, doi: [10.1097/HJH.0000000000000977](https://doi.org/10.1097/HJH.0000000000000977), indexed in Pubmed: [27228432](https://pubmed.ncbi.nlm.nih.gov/27228432/).
369. Azizi M, Sapoval M, Gosse P, et al. Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. *Lancet*. 2015; 385(9981): 1957–1965, doi: [10.1016/S0140-6736\(14\)61942-5](https://doi.org/10.1016/S0140-6736(14)61942-5), indexed in Pubmed: [25631070](https://pubmed.ncbi.nlm.nih.gov/25631070/).
370. Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. *Hypertension*. 2015; 65(2): 407–413, doi: [10.1161/HYPERTENSIONAHA.114.04019](https://doi.org/10.1161/HYPERTENSIONAHA.114.04019), indexed in Pubmed: [25421981](https://pubmed.ncbi.nlm.nih.gov/25421981/).
371. Mahfoud F, Schmieder RE, Azizi M, et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. *Eur Heart J*. 2017; 38(44): 3272–3281, doi: [10.1093/eurheartj/ehx215](https://doi.org/10.1093/eurheartj/ehx215), indexed in Pubmed: [28475773](https://pubmed.ncbi.nlm.nih.gov/28475773/).
372. Ewen S, Ukena C, Linz D, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. *Hypertension*. 2015; 65(1): 193–199, doi: [10.1161/HYPERTENSIONAHA.114.04336](https://doi.org/10.1161/HYPERTENSIONAHA.114.04336), indexed in Pubmed: [25331843](https://pubmed.ncbi.nlm.nih.gov/25331843/).
373. Mahfoud F, Bakris G, Bhatt DL, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPPLICITY HTN-3 and the Global SYMPPLICITY Registry. *Eur Heart J*. 2017; 38(2): 93–100, doi: [10.1093/eurheartj/ehw325](https://doi.org/10.1093/eurheartj/ehw325), indexed in Pubmed: [28158510](https://pubmed.ncbi.nlm.nih.gov/28158510/).
374. Burchell AE, Lobo MD, Sulke N, et al. Arteriovenous anastomosis: is this the way to control hypertension? *Hypertension*. 2014; 64(1): 6–12, doi: [10.1161/HYPERTENSIONAHA.114.02925](https://doi.org/10.1161/HYPERTENSIONAHA.114.02925), indexed in Pubmed: [24711522](https://pubmed.ncbi.nlm.nih.gov/24711522/).
375. Ng FuL, Saxena M, Mahfoud F, et al. Device-based Therapy for Hypertension. *Curr Hypertens Rep*. 2016; 18(8): 61, doi: [10.1007/s11906-016-0670-5](https://doi.org/10.1007/s11906-016-0670-5), indexed in Pubmed: [27370788](https://pubmed.ncbi.nlm.nih.gov/27370788/).
376. Faul J, Schoors D, Brouwers S, et al. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. *J Vasc Surg*. 2014; 59(4): 1078–1083, doi: [10.1016/j.jvs.2013.10.069](https://doi.org/10.1016/j.jvs.2013.10.069), indexed in Pubmed: [24484754](https://pubmed.ncbi.nlm.nih.gov/24484754/).
377. Lobo MD, Sobotka PA, Stanton A, et al. ROX CONTROL HTN Investigators. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. *Lancet*. 2015; 385(9978): 1634–1641, doi: [10.1016/S0140-6736\(14\)62053-5](https://doi.org/10.1016/S0140-6736(14)62053-5), indexed in Pubmed: [25620016](https://pubmed.ncbi.nlm.nih.gov/25620016/).
378. Ott C, Lobo MD, Sobotka PA, et al. Effect of arteriovenous anastomosis on blood pressure reduction in patients with isolated systolic hypertension compared with combined hypertension. *J Am Heart Assoc*. 2016; 5(12), doi: [10.1161/JAHA.116.004234](https://doi.org/10.1161/JAHA.116.004234), indexed in Pubmed: [28003251](https://pubmed.ncbi.nlm.nih.gov/28003251/).
379. McBryde FD, Abdala AP, Hendy EB, et al. The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension. *Nat Commun*. 2013; 4: 2395, doi: [10.1038/ncomms3395](https://doi.org/10.1038/ncomms3395), indexed in Pubmed: [24002774](https://pubmed.ncbi.nlm.nih.gov/24002774/).
380. Narkiewicz K, Ratcliffe LEK, Hart EC, et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. *JACC Basic Transl Sci*. 2016; 1(5): 313–324, doi: [10.1016/j.jacbs.2016.06.004](https://doi.org/10.1016/j.jacbs.2016.06.004), indexed in Pubmed: [27766316](https://pubmed.ncbi.nlm.nih.gov/27766316/).
381. Niewinski P, Janczak D, Rucinski A, et al. Carotid body resection for sympathetic modulation in systolic heart failure: results from

- first-in-man study. *Eur J Heart Fail.* 2017; 19(3): 391–400, doi: [10.1002/ejhf.641](https://doi.org/10.1002/ejhf.641), indexed in Pubmed: [27647775](https://pubmed.ncbi.nlm.nih.gov/27647775/).
382. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. *Circulation.* 2012; 125(13): 1635–1642, doi: [10.1161/CIRCULATIONAHA.111.068064](https://doi.org/10.1161/CIRCULATIONAHA.111.068064), indexed in Pubmed: [22379110](https://pubmed.ncbi.nlm.nih.gov/22379110/).
383. Myat A, Redwood SR, Qureshi AC, et al. Resistant hypertension. *BMJ.* 2012; 345: e7473, doi: [10.1136/bmj.e7473](https://doi.org/10.1136/bmj.e7473).
384. de la Sierra A, Banegas JR, Segura J, et al. CARDIORISC Event Investigators. Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study. *J Hypertens.* 2012; 30(4): 713–719, doi: [10.1097/HJH.0b013e328350bb40](https://doi.org/10.1097/HJH.0b013e328350bb40), indexed in Pubmed: [22306850](https://pubmed.ncbi.nlm.nih.gov/22306850/).
385. Williams B. Resistant hypertension: an unmet treatment need. *Lancet.* 2009; 374(9699): 1396–1398, doi: [10.1016/S0140-6736\(09\)61600-7](https://doi.org/10.1016/S0140-6736(09)61600-7), indexed in Pubmed: [19748666](https://pubmed.ncbi.nlm.nih.gov/19748666/).
386. Mantero F, Mattarello M, Albiger N. Detecting and Treating Primary Aldosteronism. *Exp Clin Endocrinol Diabetes.* 2007; 115(03): 171–174, doi: [10.1055/s-2007-970409](https://doi.org/10.1055/s-2007-970409).
387. Fagard R. Resistant hypertension. *Heart.* 2011; 98(3): 254–261, doi: [10.1136/heartjnl-2011-300741](https://doi.org/10.1136/heartjnl-2011-300741).
388. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. *Lancet.* 2012; 380(9841): 591–600, doi: [10.1016/S0140-6736\(12\)60825-3](https://doi.org/10.1016/S0140-6736(12)60825-3), indexed in Pubmed: [22883508](https://pubmed.ncbi.nlm.nih.gov/22883508/).
389. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. *BMJ.* 2008; 336(7653): 1114–1117, doi: [10.1136/bmj.39553.670231.25](https://doi.org/10.1136/bmj.39553.670231.25), indexed in Pubmed: [18480115](https://pubmed.ncbi.nlm.nih.gov/18480115/).
390. Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. *Hypertension.* 2010; 56(5): 824–830, doi: [10.1161/HYPERTENSIONAHA.110.156976](https://doi.org/10.1161/HYPERTENSIONAHA.110.156976), indexed in Pubmed: [20921430](https://pubmed.ncbi.nlm.nih.gov/20921430/).
391. Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. *J Hypertens.* 2013; 31(10): 2094–2102, doi: [10.1097/HJH.0b013e3283638b1a](https://doi.org/10.1097/HJH.0b013e3283638b1a), indexed in Pubmed: [24107738](https://pubmed.ncbi.nlm.nih.gov/24107738/).
392. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials. *Clin Exp Hypertens.* 2017; 39(3): 257–263, doi: [10.1080/10641963.2016.1246564](https://doi.org/10.1080/10641963.2016.1246564), indexed in Pubmed: [28448185](https://pubmed.ncbi.nlm.nih.gov/28448185/).
393. Zhao Di, Liu H, Dong P, et al. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. *Int J Cardiol.* 2017; 233: 113–117, doi: [10.1016/j.ijcard.2016.12.158](https://doi.org/10.1016/j.ijcard.2016.12.158), indexed in Pubmed: [28089457](https://pubmed.ncbi.nlm.nih.gov/28089457/).
394. Wang C, Xiong Bo, Huang J. Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials. *Heart Lung Circ.* 2016; 25(10): 1021–1030, doi: [10.1016/j.hlc.2016.02.016](https://doi.org/10.1016/j.hlc.2016.02.016), indexed in Pubmed: [27118266](https://pubmed.ncbi.nlm.nih.gov/27118266/).
395. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. *Hypertension.* 2009; 54(3): 475–481, doi: [10.1161/HYPERTENSIONAHA.109.131235](https://doi.org/10.1161/HYPERTENSIONAHA.109.131235), indexed in Pubmed: [19620517](https://pubmed.ncbi.nlm.nih.gov/19620517/).
396. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? *Eur Heart J.* 2014; 35(19): 1245–1254, doi: [10.1093/eurheartj/ehf534](https://doi.org/10.1093/eurheartj/ehf534), indexed in Pubmed: [24366917](https://pubmed.ncbi.nlm.nih.gov/24366917/).
397. Grossman A, Messerli FH, Grossman E. Drug induced hypertension — An unappreciated cause of secondary hypertension. *Eur J Pharmacol.* 2015; 763(Pt A): 15–22, doi: [10.1016/j.ejphar.2015.06.027](https://doi.org/10.1016/j.ejphar.2015.06.027), indexed in Pubmed: [26096556](https://pubmed.ncbi.nlm.nih.gov/26096556/).
398. van den Born BJH, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. *Eur Heart J Cardiovasc Pharmacother.* 2018 [Epub ahead of print], doi: [10.1093/ehjcvp/pvy032](https://doi.org/10.1093/ehjcvp/pvy032), indexed in Pubmed: [30165588](https://pubmed.ncbi.nlm.nih.gov/30165588/).
399. Vaughan CJ, Delanty N. Hypertensive emergencies. *Lancet.* 2000; 356(9227): 411–417, doi: [10.1016/S0140-6736\(00\)02539-3](https://doi.org/10.1016/S0140-6736(00)02539-3), indexed in Pubmed: [10972386](https://pubmed.ncbi.nlm.nih.gov/10972386/).
400. Chester EM, Agamanolis DP, Banker BQ, et al. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. *Neurology.* 1978; 28(9 Pt 1): 928–939, indexed in Pubmed: [567764](https://pubmed.ncbi.nlm.nih.gov/567764/).
401. van den Born BJH, Koopmans RP, Groeneveld JO, et al. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. *J Hypertens.* 2006; 24(11): 2299–2304, doi: [10.1097/01.hjh.0000249710.21146.38](https://doi.org/10.1097/01.hjh.0000249710.21146.38), indexed in Pubmed: [17053554](https://pubmed.ncbi.nlm.nih.gov/17053554/).
402. Cremer A, Amraoui F, Lip GYH, et al. From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. *J Hum Hypertens.* 2016; 30(8): 463–466, doi: [10.1038/jhh.2015.112](https://doi.org/10.1038/jhh.2015.112), indexed in Pubmed: [26582411](https://pubmed.ncbi.nlm.nih.gov/26582411/).
403. Pinna G, Pascale C, Fornengo P, et al. Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study. *PLoS One.* 2014; 9(4): e93542, doi: [10.1371/journal.pone.0093542](https://doi.org/10.1371/journal.pone.0093542), indexed in Pubmed: [24695800](https://pubmed.ncbi.nlm.nih.gov/24695800/).
404. van den Born BJH, Löwenberg EC, van der Hoeven NV, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. *J Hypertens.* 2011; 29(5): 922–927, doi: [10.1097/HJH.0b013e328345023d](https://doi.org/10.1097/HJH.0b013e328345023d), indexed in Pubmed: [21372741](https://pubmed.ncbi.nlm.nih.gov/21372741/).
405. Grassi D, O'Flaherty M, Pellizzari M, et al. Group of Investigators of the REHASE Program. Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. *J Clin Hypertens (Greenwich).* 2008; 10(9): 662–667, doi: [10.1111/j.1751-7176.2008.00001.x](https://doi.org/10.1111/j.1751-7176.2008.00001.x), indexed in Pubmed: [18844760](https://pubmed.ncbi.nlm.nih.gov/18844760/).
406. Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. *J Hum Hypertens.* 2008; 22(9): 596–607, doi: [10.1038/jhh.2008.25](https://doi.org/10.1038/jhh.2008.25), indexed in Pubmed: [18418399](https://pubmed.ncbi.nlm.nih.gov/18418399/).
407. Lane DA, Lip GYH, Beevers DG. Improving survival of malignant hypertension patients over 40 years. *Am J Hypertens.* 2009; 22(11): 1199–1204, doi: [10.1038/ajh.2009.153](https://doi.org/10.1038/ajh.2009.153), indexed in Pubmed: [19696746](https://pubmed.ncbi.nlm.nih.gov/19696746/).
408. Amraoui F, Van Der Hoeven NV, Van Valkengoed IGM, et al. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. *J Clin Hypertens (Greenwich).* 2014; 16(2): 122–126, doi: [10.1111/jch.12243](https://doi.org/10.1111/jch.12243), indexed in Pubmed: [24373528](https://pubmed.ncbi.nlm.nih.gov/24373528/).
409. González R, Morales E, Segura J, et al. Long-term renal survival in malignant hypertension. *Nephrol Dial Transplant.* 2010; 25(10): 3266–3272, doi: [10.1093/ndt/gfq143](https://doi.org/10.1093/ndt/gfq143), indexed in Pubmed: [20299339](https://pubmed.ncbi.nlm.nih.gov/20299339/).
410. Cuspidi C, Rescaldani M, Tadic M, et al. White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis. *J Hypertens.* 2015; 33(1): 24–32, doi: [10.1097/HJH.0000000000000416](https://doi.org/10.1097/HJH.0000000000000416), indexed in Pubmed: [25380162](https://pubmed.ncbi.nlm.nih.gov/25380162/).
411. Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. *J Hypertens.* 2009; 27(8): 1672–1678, doi: [10.1097/hjh.0b013e32832be5f9](https://doi.org/10.1097/hjh.0b013e32832be5f9).
412. Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. *J Am Coll Cardiol.* 2015; 66(20): 2159–2169, doi: [10.1016/j.jacc.2015.09.007](https://doi.org/10.1016/j.jacc.2015.09.007), indexed in Pubmed: [26564592](https://pubmed.ncbi.nlm.nih.gov/26564592/).
413. Fagard RH, Staessen JA, Thijs L, et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. *Circulation.* 2000; 102(10): 1139–1144, indexed in Pubmed: [10973843](https://pubmed.ncbi.nlm.nih.gov/10973843/).
414. Mancia G, Facchetti R, Parati G, et al. Effect of long-term antihypertensive treatment on white-coat hypertension. *Hypertension.* 2014; 64(6): 1388–1398, doi: [10.1161/HYPERTENSIONAHA.114.04278](https://doi.org/10.1161/HYPERTENSIONAHA.114.04278), indexed in Pubmed: [25245386](https://pubmed.ncbi.nlm.nih.gov/25245386/).
415. Staessen JA, Celis H, Thijs L, et al. Efficacy of antihypertensive drugs given once a day: the calcium antagonists revisited. *J Hypertens Suppl.* 1994; 12(8): S107–S115, indexed in Pubmed: [7707149](https://pubmed.ncbi.nlm.nih.gov/7707149/).
416. Bulpitt CJ, Beckett NS, Peters R, et al. Blood pressure control in the Hypertension in the Very Elderly Trial (HYVET). *J Hum Hypertens.* 2011; 26(3): 157–163, doi: [10.1038/jhh.2011.10](https://doi.org/10.1038/jhh.2011.10).
417. Franklin SS, Thijs L, Asayama K, et al. IDACO Investigators. The Cardiovascular Risk of White-Coat Hypertension. *J Am Coll Cardiol.* 2016; 68(19): 2033–2043, doi: [10.1016/j.jacc.2016.08.035](https://doi.org/10.1016/j.jacc.2016.08.035), indexed in Pubmed: [27810041](https://pubmed.ncbi.nlm.nih.gov/27810041/).

418. Franklin SS, Thijs L, Hansen TW, et al. International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. *Hypertension*. 2012; 59(3): 564–571, doi: [10.1161/HYPERTENSIONAHA.111.180653](https://doi.org/10.1161/HYPERTENSIONAHA.111.180653), indexed in Pubmed: [22252396](https://pubmed.ncbi.nlm.nih.gov/22252396/).
419. Mancia G, Bombelli M, Brambilla G, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. *Hypertension*. 2013; 62(1): 168–174, doi: [10.1161/HYPERTENSIONAHA.111.00690](https://doi.org/10.1161/HYPERTENSIONAHA.111.00690), indexed in Pubmed: [23716584](https://pubmed.ncbi.nlm.nih.gov/23716584/).
420. Mancia G, Facchetti R, Grassi G, et al. Adverse prognostic value of persistent office blood pressure elevation in white coat hypertension. *Hypertension*. 2015; 66(2): 437–444, doi: [10.1161/HYPERTENSIONAHA.115.05367](https://doi.org/10.1161/HYPERTENSIONAHA.115.05367), indexed in Pubmed: [26056342](https://pubmed.ncbi.nlm.nih.gov/26056342/).
421. Gorostidi M, Banegas JR, de la Sierra A, et al. Ambulatory blood pressure monitoring in daily clinical practice — the Spanish ABPM Registry experience. *Eur J Clin Invest*. 2016; 46(1): 92–98, doi: [10.1111/eci.12565](https://doi.org/10.1111/eci.12565), indexed in Pubmed: [26541761](https://pubmed.ncbi.nlm.nih.gov/26541761/).
422. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. *Hypertension*. 2009; 54(2): 226–232, doi: [10.1161/hypertensionaha.109.129882](https://doi.org/10.1161/hypertensionaha.109.129882).
423. Ogedegbe G, Agyemang C, Ravenell JE. Masked hypertension: evidence of the need to treat. *Curr Hypertens Rep*. 2010; 12(5): 349–355, doi: [10.1007/s11906-010-0140-4](https://doi.org/10.1007/s11906-010-0140-4), indexed in Pubmed: [20694858](https://pubmed.ncbi.nlm.nih.gov/20694858/).
424. Sundström J, Neovius M, Tynelius P, et al. Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. *BMJ*. 2011; 342: d643, indexed in Pubmed: [21343202](https://pubmed.ncbi.nlm.nih.gov/21343202/).
425. Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. *Circ Res*. 2015; 116(6): 1058–1073, doi: [10.1161/CIRCRESAHA.116.303641](https://doi.org/10.1161/CIRCRESAHA.116.303641), indexed in Pubmed: [25767290](https://pubmed.ncbi.nlm.nih.gov/25767290/).
426. Williams B. High blood pressure in young people and premature death. *BMJ*. 2011; 342: d1104, indexed in Pubmed: [21343188](https://pubmed.ncbi.nlm.nih.gov/21343188/).
427. Julius S, Nesbitt SD, Egan BM, et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Engl J Med*. 2006; 354(16): 1685–1697, doi: [10.1056/NEJMoa060838](https://doi.org/10.1056/NEJMoa060838), indexed in Pubmed: [16537662](https://pubmed.ncbi.nlm.nih.gov/16537662/).
428. O'Rourke MF, Adji A. Guidelines on guidelines: focus on isolated systolic hypertension in youth. *J Hypertens*. 2013; 31(4): 649–654, doi: [10.1097/HJH.0b013e32835d8230](https://doi.org/10.1097/HJH.0b013e32835d8230), indexed in Pubmed: [23412425](https://pubmed.ncbi.nlm.nih.gov/23412425/).
429. Yano Y, Stamler J, Garside DB, et al. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. *J Am Coll Cardiol*. 2015; 65(4): 327–335, doi: [10.1016/j.jacc.2014.10.060](https://doi.org/10.1016/j.jacc.2014.10.060), indexed in Pubmed: [25634830](https://pubmed.ncbi.nlm.nih.gov/25634830/).
430. Palatini P, Mormino P, Canali C, et al. Factors affecting ambulatory blood pressure reproducibility. Results of the HARVEST Trial. *Hypertension and Ambulatory Recording Venetia Study*. *Hypertension*. 1994; 23(2): 211–216, indexed in Pubmed: [8307631](https://pubmed.ncbi.nlm.nih.gov/8307631/).
431. Briasoulis A, Agarwal V, Tousoulis D, et al. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised-controlled studies. *Heart*. 2014; 100(4): 317–323, doi: [10.1136/heartjnl-2013-304111](https://doi.org/10.1136/heartjnl-2013-304111), indexed in Pubmed: [23813846](https://pubmed.ncbi.nlm.nih.gov/23813846/).
432. Corrao G, Rea F, Monzio Compagnoni M, et al. Protective effects of antihypertensive treatment in patients aged 85 years or older. *J Hypertens*. 2017; 35(7): 1432–1441, doi: [10.1097/HJH.0000000000001323](https://doi.org/10.1097/HJH.0000000000001323), indexed in Pubmed: [28319595](https://pubmed.ncbi.nlm.nih.gov/28319595/).
433. Corrao G, Mazzola P, Monzio Compagnoni M, et al. Antihypertensive medications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81,617 Italian patients newly treated between 2005 and 2009. *Drugs Aging*. 2015; 32(11): 927–936, doi: [10.1007/s40266-015-0306-5](https://doi.org/10.1007/s40266-015-0306-5), indexed in Pubmed: [26589307](https://pubmed.ncbi.nlm.nih.gov/26589307/).
434. Kjeldsen SE, Stenehjem A, Os I, et al. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. *Blood Press*. 2016; 25(6): 333–336, doi: [10.1080/08037051.2016.1236329](https://doi.org/10.1080/08037051.2016.1236329), indexed in Pubmed: [27644446](https://pubmed.ncbi.nlm.nih.gov/27644446/).
435. ESC Committee for Practice Guidelines. Guidelines on the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018; 39(34): 3165–3241, doi: [10.1093/eurheartj/ehy340](https://doi.org/10.1093/eurheartj/ehy340).
436. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol*. 2013; 122(5): 1122–1131, doi: [10.1097/01.AOG.0000437382.03963.88](https://doi.org/10.1097/01.AOG.0000437382.03963.88), indexed in Pubmed: [24150027](https://pubmed.ncbi.nlm.nih.gov/24150027/).
437. Lowe SA, Bowyer L, Lust K, et al. Society of Obstetric Medicine of Australia and New Zealand. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy. *Aust N Z J Obstet Gynaecol*. 2015; 55(1): 11–16, doi: [10.1111/ajo.12253](https://doi.org/10.1111/ajo.12253), indexed in Pubmed: [25308532](https://pubmed.ncbi.nlm.nih.gov/25308532/).
438. Bartsch E, Medcalf KE, Park AL, et al. High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *BMJ*. 2016; 353: i1753, indexed in Pubmed: [27094586](https://pubmed.ncbi.nlm.nih.gov/27094586/).
439. Blood Pressure Association. Blood Pressure UK. <http://www.bloodpressureuk.org> (20.04.2018).
440. Waugh J, Perry IJ, Halligan AW, et al. Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? *Am J Obstet Gynecol*. 1998; 178(3): 521–526, indexed in Pubmed: [9539520](https://pubmed.ncbi.nlm.nih.gov/9539520/).
441. Schmella MJ, Clifton RG, Althouse AD, et al. Uric Acid Determination in Gestational Hypertension: Is it as Effective a Delineator of Risk as Proteinuria in High-Risk Women? *Reprod Sci*. 2015; 22(10): 1212–1219, doi: [10.1177/1933719115572477](https://doi.org/10.1177/1933719115572477), indexed in Pubmed: [25717062](https://pubmed.ncbi.nlm.nih.gov/25717062/).
442. Chappell LC, Shennan AH. Assessment of proteinuria in pregnancy. *BMJ*. 2008; 336(7651): 968–969, doi: [10.1136/bmj.39540.657928.BE](https://doi.org/10.1136/bmj.39540.657928.BE), indexed in Pubmed: [18403497](https://pubmed.ncbi.nlm.nih.gov/18403497/).
443. Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. *CMAJ*. 2008; 178(6): 701–711, doi: [10.1503/cmaj.070430](https://doi.org/10.1503/cmaj.070430), indexed in Pubmed: [18332385](https://pubmed.ncbi.nlm.nih.gov/18332385/).
444. Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med*. 2016; 374(1): 13–22, doi: [10.1056/NEJMoa1414838](https://doi.org/10.1056/NEJMoa1414838), indexed in Pubmed: [26735990](https://pubmed.ncbi.nlm.nih.gov/26735990/).
445. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. *N Engl J Med*. 2017; 377(7): 613–622, doi: [10.1056/NEJMoa1704559](https://doi.org/10.1056/NEJMoa1704559), indexed in Pubmed: [28657417](https://pubmed.ncbi.nlm.nih.gov/28657417/).
446. Magee LA, von Dadelszen P, Singer J, et al. CHIPS Study Group*. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure? *Hypertension*. 2016; 68(5): 1153–1159, doi: [10.1161/HYPERTENSIONAHA.116.07862](https://doi.org/10.1161/HYPERTENSIONAHA.116.07862), indexed in Pubmed: [27620393](https://pubmed.ncbi.nlm.nih.gov/27620393/).
447. Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. *Lancet*. 1976; 2(7989): 753–756, indexed in Pubmed: [61439](https://pubmed.ncbi.nlm.nih.gov/61439/).
448. Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. *Lancet*. 1982; 1(8273): 647–649, indexed in Pubmed: [6121965](https://pubmed.ncbi.nlm.nih.gov/6121965/).
449. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). *Eur Heart J*. 2011; 32(24): 3147–3197, doi: [10.1093/eurheartj/ehr218](https://doi.org/10.1093/eurheartj/ehr218), indexed in Pubmed: [21873418](https://pubmed.ncbi.nlm.nih.gov/21873418/).
450. Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev*. 2014; 2: CD002252.
451. Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. *BMJ*. 2003; 327(7421): 955–960, doi: [10.1136/bmj.327.7421.955](https://doi.org/10.1136/bmj.327.7421.955), indexed in Pubmed: [14576246](https://pubmed.ncbi.nlm.nih.gov/14576246/).

452. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. *Cochrane Database Syst Rev.* 2006(3): CD001449, doi: [10.1002/14651858.CD001449.pub2](https://doi.org/10.1002/14651858.CD001449.pub2), indexed in Pubmed: [16855969](https://pubmed.ncbi.nlm.nih.gov/16855969/).
453. Koopmans CM, Bijlenga D, Groen H, et al. HYPITAT study group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. *Lancet.* 2009; 374(9694): 979–988, doi: [10.1016/S0140-6736\(09\)60736-4](https://doi.org/10.1016/S0140-6736(09)60736-4), indexed in Pubmed: [19656558](https://pubmed.ncbi.nlm.nih.gov/19656558/).
454. Ray JG, Vermeulen MJ, Schull MJ, et al. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet.* 2005; 366(9499): 1797–1803, doi: [10.1016/S0140-6736\(05\)67726-4](https://doi.org/10.1016/S0140-6736(05)67726-4), indexed in Pubmed: [16298217](https://pubmed.ncbi.nlm.nih.gov/16298217/).
455. Black MH, Zhou H, Sacks DA, et al. Hypertensive disorders first identified in pregnancy increase risk for incident prehypertension and hypertension in the year after delivery. *J Hypertens.* 2016; 34(4): 728–735, doi: [10.1097/HJH.0000000000000855](https://doi.org/10.1097/HJH.0000000000000855), indexed in Pubmed: [26809018](https://pubmed.ncbi.nlm.nih.gov/26809018/).
456. Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. *Circulation.* 1996; 94(3): 483–489, indexed in Pubmed: [8759093](https://pubmed.ncbi.nlm.nih.gov/8759093/).
457. Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. *J Hypertens.* 1997; 15(10): 1063–1068, indexed in Pubmed: [9350579](https://pubmed.ncbi.nlm.nih.gov/9350579/).
458. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. *JAMA.* 2000; 284(1): 72–78, indexed in Pubmed: [10872016](https://pubmed.ncbi.nlm.nih.gov/10872016/).
459. World Health Organization. Medical eligibility criteria for contraceptive use. Third edition, 2004. <http://apps.who.int/iris/bitstream/10665/42907/1/9241562668.pdf> (28.06.2018).
460. Lubianca JN, Moreira LB, Gus M, et al. Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension. *J Hum Hypertens.* 2005; 19(6): 451–455, doi: [10.1038/sj.jhh.1001841](https://doi.org/10.1038/sj.jhh.1001841), indexed in Pubmed: [15759027](https://pubmed.ncbi.nlm.nih.gov/15759027/).
461. Mosca L, Benjamin EJ, Berra K, et al. American Heart Association. Effectiveness-based guidelines for the prevention of cardiovascular disease in women — 2011 update: a guideline from the American Heart Association. *J Am Coll Cardiol.* 2011; 57(12): 1404–1423, doi: [10.1016/j.jacc.2011.02.005](https://doi.org/10.1016/j.jacc.2011.02.005), indexed in Pubmed: [21388771](https://pubmed.ncbi.nlm.nih.gov/21388771/).
462. Issa Z, Seely EW, Rahme M, et al. Effects of hormone therapy on blood pressure. *Menopause.* 2015; 22(4): 456–468, doi: [10.1097/GME.0000000000000322](https://doi.org/10.1097/GME.0000000000000322), indexed in Pubmed: [25268408](https://pubmed.ncbi.nlm.nih.gov/25268408/).
463. Modesti PA, Reboldi G, Cappuccio FP, et al. ESH Working Group on CV Risk in Low Resource Settings. Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. *PLoS One.* 2016; 11(1): e0147601, doi: [10.1371/journal.pone.0147601](https://doi.org/10.1371/journal.pone.0147601), indexed in Pubmed: [26808317](https://pubmed.ncbi.nlm.nih.gov/26808317/).
464. Whelton PK, Einhorn PT, Muntner P, et al. National Heart, Lung, and Blood Institute Working Group on Research Needs to Improve Hypertension Treatment and Control in African Americans. Research needs to improve hypertension treatment and control in African Americans. *Hypertension.* 2016; 68(5): 1066–1072, doi: [10.1161/HYPERTENSIONAHA.116.07905](https://doi.org/10.1161/HYPERTENSIONAHA.116.07905), indexed in Pubmed: [27620388](https://pubmed.ncbi.nlm.nih.gov/27620388/).
465. Kaufman JS, Cooper RS, McGee DL. Socioeconomic status and health in blacks and whites: the problem of residual confounding and the resiliency of race. *Epidemiology.* 1997; 8(6): 621–628, indexed in Pubmed: [9345660](https://pubmed.ncbi.nlm.nih.gov/9345660/).
466. Agyemang C, van Oeffelen AA, Norredam M, et al. Socioeconomic inequalities in stroke incidence among migrant groups: analysis of nationwide data. *Stroke.* 2014; 45(8): 2397–2403, doi: [10.1161/STROKEAHA.114.005505](https://doi.org/10.1161/STROKEAHA.114.005505), indexed in Pubmed: [24938846](https://pubmed.ncbi.nlm.nih.gov/24938846/).
467. Mehanna M, Gong Y, McDonough CW, et al. Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. *J Clin Hypertens (Greenwich).* 2017; 19(12): 1301–1308, doi: [10.1111/jch.13094](https://doi.org/10.1111/jch.13094), indexed in Pubmed: [28940643](https://pubmed.ncbi.nlm.nih.gov/28940643/).
468. Erlinger TP, Vollmer WM, Svetkey LP, et al. The potential impact of nonpharmacologic population-wide blood pressure reduction on coronary heart disease events: pronounced benefits in African-Americans and hypertensives. *Prev Med.* 2003; 37(4): 327–333, indexed in Pubmed: [14507489](https://pubmed.ncbi.nlm.nih.gov/14507489/).
469. Wright JT, Dunn JK, Cutler JA, et al. ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. *JAMA.* 2005; 293(13): 1595–1608, doi: [10.1001/jama.293.13.1595](https://doi.org/10.1001/jama.293.13.1595), indexed in Pubmed: [15811979](https://pubmed.ncbi.nlm.nih.gov/15811979/).
470. Wright JT, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med.* 2008; 168(2): 207–217, doi: [10.1001/archinternmed.2007.66](https://doi.org/10.1001/archinternmed.2007.66), indexed in Pubmed: [18227370](https://pubmed.ncbi.nlm.nih.gov/18227370/).
471. Agyemang C, Nyaaba G, Beune E, et al. Variations in hypertension awareness, treatment, and control among Ghanaian migrants living in Amsterdam, Berlin, London, and nonmigrant Ghanaians living in rural and urban Ghana — the RODAM study. *J Hypertens.* 2018; 36(1): 169–177, doi: [10.1097/HJH.0000000000001520](https://doi.org/10.1097/HJH.0000000000001520), indexed in Pubmed: [28858173](https://pubmed.ncbi.nlm.nih.gov/28858173/).
472. Wijkman M, Länne T, Engvall J, et al. Masked nocturnal hypertension — a novel marker of risk in type 2 diabetes. *Diabetologia.* 2009; 52(7): 1258–1264, doi: [10.1007/s00125-009-1369-9](https://doi.org/10.1007/s00125-009-1369-9), indexed in Pubmed: [19396423](https://pubmed.ncbi.nlm.nih.gov/19396423/).
473. Mann JFE, Schmieder RE, McQueen M, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet.* 2008; 372(9638): 547–553, doi: [10.1016/S0140-6736\(08\)61236-2](https://doi.org/10.1016/S0140-6736(08)61236-2), indexed in Pubmed: [18707986](https://pubmed.ncbi.nlm.nih.gov/18707986/).
474. Persson F, Lewis JB, Lewis EJ, et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. *Clin J Am Soc Nephrol.* 2011; 6(5): 1025–1031, doi: [10.2215/CJN.07590810](https://doi.org/10.2215/CJN.07590810), indexed in Pubmed: [21350110](https://pubmed.ncbi.nlm.nih.gov/21350110/).
475. Zinman B, Lachin JM, Inzucchi SE, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015; 373(22): 2117–2128, doi: [10.1056/NEJMoa1504720](https://doi.org/10.1056/NEJMoa1504720), indexed in Pubmed: [26378978](https://pubmed.ncbi.nlm.nih.gov/26378978/).
476. Neal B, Perkovic V, Mahaffey K, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med.* 2017; 377(7): 644–657, doi: [10.1056/nejmoa1611925](https://doi.org/10.1056/nejmoa1611925).
477. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). *Circulation.* 2011; 124(16): 1727–1736, doi: [10.1161/CIRCULATIONAHA.110.008870](https://doi.org/10.1161/CIRCULATIONAHA.110.008870), indexed in Pubmed: [21947289](https://pubmed.ncbi.nlm.nih.gov/21947289/).
478. Wanner C, Inzucchi S, Lachin J, et al. EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med.* 2016; 375(4): 323–334, doi: [10.1056/nejmoa1515920](https://doi.org/10.1056/nejmoa1515920).
479. Mancia G, Cannon CP, Tikkanen I, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. *Hypertension.* 2016; 68(6): 1355–1364, doi: [10.1161/HYPERTENSIONAHA.116.07703](https://doi.org/10.1161/HYPERTENSIONAHA.116.07703), indexed in Pubmed: [27977392](https://pubmed.ncbi.nlm.nih.gov/27977392/).
480. Buse JB. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2016; 375(18): 1797–1799, doi: [10.1056/nejmc1611289](https://doi.org/10.1056/nejmc1611289).
481. Bethel MA, Patel RA, Merrill P, et al. EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. *Lancet Diabetes Endocrinol.* 2018; 6(2): 105–113, doi: [10.1016/S2213-8587\(17\)30412-6](https://doi.org/10.1016/S2213-8587(17)30412-6), indexed in Pubmed: [29221659](https://pubmed.ncbi.nlm.nih.gov/29221659/).
482. Thomopoulos C, Parati G, Zanchetti A, et al. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels — overview and meta-analyses of randomized trials. *J Hypertens.* 2014; 32(12): 2296–2304, doi: [10.1097/HJH.0000000000000379](https://doi.org/10.1097/HJH.0000000000000379), indexed in Pubmed: [25259547](https://pubmed.ncbi.nlm.nih.gov/25259547/).

483. Drawz PE, Alper AB, Anderson AH, et al. Chronic Renal Insufficiency Cohort Study Investigators. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. *Clin J Am Soc Nephrol*. 2016; 11(4): 642–652, doi: [10.2215/CJN.08530815](https://doi.org/10.2215/CJN.08530815), indexed in Pubmed: [26912547](https://pubmed.ncbi.nlm.nih.gov/26912547/).
484. Rossignol P, Massy ZA, Azizi M, et al. ERA-EDTA EURECA-m working group, Red de Investigación Renal (REDINREN) network, Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network. The double challenge of resistant hypertension and chronic kidney disease. *Lancet*. 2015; 386(10003): 1588–1598, doi: [10.1016/S0140-6736\(15\)00418-3](https://doi.org/10.1016/S0140-6736(15)00418-3), indexed in Pubmed: [26530623](https://pubmed.ncbi.nlm.nih.gov/26530623/).
485. Malhotra R, Nguyen HA, Benavente O, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. *JAMA Intern Med*. 2017; 177(10): 1498–1505, doi: [10.1001/jamainternmed.2017.4377](https://doi.org/10.1001/jamainternmed.2017.4377), indexed in Pubmed: [28873137](https://pubmed.ncbi.nlm.nih.gov/28873137/).
486. de Zeeuw D, de Graeff PA, Laverman GD, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation*. 2004; 110(8): 921–927, doi: [10.1161/01.CIR.0000139860.33974.28](https://doi.org/10.1161/01.CIR.0000139860.33974.28), indexed in Pubmed: [15302780](https://pubmed.ncbi.nlm.nih.gov/15302780/).
487. Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Ann Intern Med*. 2003; 139(4): 244–252, indexed in Pubmed: [12965979](https://pubmed.ncbi.nlm.nih.gov/12965979/).
488. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. *Ann Intern Med*. 2011; 154(8): 541–548, doi: [10.7326/0003-4819-154-8-201104190-00335](https://doi.org/10.7326/0003-4819-154-8-201104190-00335), indexed in Pubmed: [21403055](https://pubmed.ncbi.nlm.nih.gov/21403055/).
489. Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. *J Am Coll Cardiol*. 2014; 64(6): 588–597, doi: [10.1016/j.jacc.2014.04.065](https://doi.org/10.1016/j.jacc.2014.04.065), indexed in Pubmed: [25104529](https://pubmed.ncbi.nlm.nih.gov/25104529/).
490. Farsang CK, Kiss I, Tykarski A, et al. Treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD). *J Hypertens*. 2016; 17(62): 1–2.
491. Baker JG, Wilcox RG. -Blockers, heart disease and COPD: current controversies and uncertainties. *Thorax*. 2017; 72(3): 271–276, doi: [10.1136/thoraxjnl-2016-208412](https://doi.org/10.1136/thoraxjnl-2016-208412), indexed in Pubmed: [27927840](https://pubmed.ncbi.nlm.nih.gov/27927840/).
492. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. *Ann Intern Med*. 2006; 144(12): 904–912, indexed in Pubmed: [16754916](https://pubmed.ncbi.nlm.nih.gov/16754916/).
493. Rutten FH, Zuihoff NPA, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. *Arch Intern Med*. 2010; 170(10): 880–887, doi: [10.1001/archinternmed.2010.112](https://doi.org/10.1001/archinternmed.2010.112), indexed in Pubmed: [20498416](https://pubmed.ncbi.nlm.nih.gov/20498416/).
494. Coiro S, Girerd N, Rossignol P, et al. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. *Eur J Heart Fail*. 2017; 19(2): 271–279, doi: [10.1002/ehfj.647](https://doi.org/10.1002/ehfj.647), indexed in Pubmed: [27774703](https://pubmed.ncbi.nlm.nih.gov/27774703/).
495. Cazzola M, Noschese P, D'Amato G, et al. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. *Chest*. 2002; 121(1): 230–241, indexed in Pubmed: [11796456](https://pubmed.ncbi.nlm.nih.gov/11796456/).
496. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. *Lancet*. 2016; 387(10017): 435–443, doi: [10.1016/S0140-6736\(15\)00805-3](https://doi.org/10.1016/S0140-6736(15)00805-3), indexed in Pubmed: [26559744](https://pubmed.ncbi.nlm.nih.gov/26559744/).
497. Bangalore S, Messerli FH, Wun CC, et al. Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of the Treating to New Targets (TNT) Trial. *J Am Coll Cardiol*. 2019; 53: A217.
498. Bangalore S, Qin J, Sloan S, et al. PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. *Circulation*. 2010; 122(21): 2142–2151, doi: [10.1161/CIRCULATIONAHA.109.905687](https://doi.org/10.1161/CIRCULATIONAHA.109.905687), indexed in Pubmed: [21060068](https://pubmed.ncbi.nlm.nih.gov/21060068/).
499. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? *Ann Intern Med*. 2006; 144(12): 884–893, indexed in Pubmed: [16785477](https://pubmed.ncbi.nlm.nih.gov/16785477/).
500. Sleight P, Redon J, Verdecchia P, et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. *J Hypertens*. 2009; 27(7): 1360–1369, doi: [10.1097/HJH.0b013e3283232d7370](https://doi.org/10.1097/HJH.0b013e3283232d7370), indexed in Pubmed: [19506526](https://pubmed.ncbi.nlm.nih.gov/19506526/).
501. Vidal-Petiot E, Ford I, Greenlaw N, et al. CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. *Lancet*. 2016; 388(10056): 2142–2152, doi: [10.1016/S0140-6736\(16\)31326-5](https://doi.org/10.1016/S0140-6736(16)31326-5), indexed in Pubmed: [27590221](https://pubmed.ncbi.nlm.nih.gov/27590221/).
502. Redon J, Mancia G, Sleight P, et al. ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). *J Am Coll Cardiol*. 2012; 59(1): 74–83, doi: [10.1016/j.jacc.2011.09.040](https://doi.org/10.1016/j.jacc.2011.09.040), indexed in Pubmed: [22192672](https://pubmed.ncbi.nlm.nih.gov/22192672/).
503. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009; 338: b1665, doi: [10.1136/bmj.b1665](https://doi.org/10.1136/bmj.b1665), indexed in Pubmed: [19454737](https://pubmed.ncbi.nlm.nih.gov/19454737/).
504. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure—meta-analyses of randomized trials. *J Hypertens*. 2016; 34(3): 373–84; discussion 384, doi: [10.1097/HJH.0000000000000848](https://doi.org/10.1097/HJH.0000000000000848), indexed in Pubmed: [26780184](https://pubmed.ncbi.nlm.nih.gov/26780184/).
505. Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: action to control cardiovascular risk in diabetes blood pressure trial. *Hypertension*. 2015; 66(6): 1123–1129, doi: [10.1161/HYPERTENSIONAHA.115.06236](https://doi.org/10.1161/HYPERTENSIONAHA.115.06236), indexed in Pubmed: [26459421](https://pubmed.ncbi.nlm.nih.gov/26459421/).
506. Verdecchia P, Staessen JA, Angeli F, et al. Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. *Lancet*. 2009; 374(9689): 525–533, doi: [10.1016/S0140-6736\(09\)61340-4](https://doi.org/10.1016/S0140-6736(09)61340-4), indexed in Pubmed: [19683638](https://pubmed.ncbi.nlm.nih.gov/19683638/).
507. McMurray JVV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Coordinators, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014; 371(11): 993–1004, doi: [10.1056/NEJMoa1409077](https://doi.org/10.1056/NEJMoa1409077), indexed in Pubmed: [25176015](https://pubmed.ncbi.nlm.nih.gov/25176015/).
508. Manning LS, Mistri AK, Potter J, et al. Short-term blood pressure variability in acute stroke: post hoc analysis of the controlling hypertension and hypotension immediately post stroke and continue or stop post-stroke antihypertensives collaborative study trials. *Stroke*. 2015; 46(6): 1518–1524, doi: [10.1161/STROKEAHA.115.009078](https://doi.org/10.1161/STROKEAHA.115.009078), indexed in Pubmed: [25908462](https://pubmed.ncbi.nlm.nih.gov/25908462/).
509. Rodriguez-Luna D, Piñeiro S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. *Eur J Neurol*. 2013; 20(9): 1277–1283, doi: [10.1111/ene.12180](https://doi.org/10.1111/ene.12180), indexed in Pubmed: [23647568](https://pubmed.ncbi.nlm.nih.gov/23647568/).
510. Sakamoto Y, Koga M, Yamagami H, et al. SAMURAI Study Investigators. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. *Stroke*. 2013; 44(7): 1846–1851, doi: [10.1161/STROKEAHA.113.001212](https://doi.org/10.1161/STROKEAHA.113.001212), indexed in Pubmed: [23704107](https://pubmed.ncbi.nlm.nih.gov/23704107/).
511. Anderson CS, Heeley E, Huang Y, et al. INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med*. 2013; 368(25): 2355–2365, doi: [10.1056/NEJMoa1214609](https://doi.org/10.1056/NEJMoa1214609), indexed in Pubmed: [23713578](https://pubmed.ncbi.nlm.nih.gov/23713578/).

512. Qureshi A, Palesch Y, Barsan W, et al. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. *New England Journal of Medicine*. 2016; 375(11): 1033–1043, doi: [10.1056/nejmoa1603460](https://doi.org/10.1056/nejmoa1603460).
513. Tsivgoulis G, Katsanos AH, Tsivgoulis G, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. *Neurology*. 2014; 83(17): 1523–1529, doi: [10.1212/WNL.0000000000000917](https://doi.org/10.1212/WNL.0000000000000917), indexed in Pubmed: [25239836](https://pubmed.ncbi.nlm.nih.gov/25239836/).
514. Ahmed N, Wahlgren N, Brainin M, et al. SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke — International Stroke Thrombolysis Register (SITS-ISTR). *Stroke*. 2009; 40(7): 2442–2449, doi: [10.1161/STROKEAHA.109.548602](https://doi.org/10.1161/STROKEAHA.109.548602), indexed in Pubmed: [19461022](https://pubmed.ncbi.nlm.nih.gov/19461022/).
515. Wu W, Huo X, Zhao X, et al. TIMS-CHINA investigators. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS-China Study. *PLoS One*. 2016; 11(2): e0144260, doi: [10.1371/journal.pone.0144260](https://doi.org/10.1371/journal.pone.0144260), indexed in Pubmed: [26828609](https://pubmed.ncbi.nlm.nih.gov/26828609/).
516. Lee M, Ovbiagele B, Hong KS, et al. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. *Stroke*. 2015; 46(7): 1883–1889, doi: [10.1161/STROKEAHA.115.009552](https://doi.org/10.1161/STROKEAHA.115.009552), indexed in Pubmed: [26022636](https://pubmed.ncbi.nlm.nih.gov/26022636/).
517. Zhao R, Liu FD, Wang S, et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long-term dependency or mortality: a meta-analysis of current literature. *Medicine (Baltimore)*. 2015; 94(23): e896, doi: [10.1097/MD.0000000000000896](https://doi.org/10.1097/MD.0000000000000896), indexed in Pubmed: [26061309](https://pubmed.ncbi.nlm.nih.gov/26061309/).
518. Jauch EC, Saver JL, Adams HP, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2013; 44(3): 870–947, doi: [10.1161/STR.0b013e318284056a](https://doi.org/10.1161/STR.0b013e318284056a), indexed in Pubmed: [23370205](https://pubmed.ncbi.nlm.nih.gov/23370205/).
519. Sandset EC, Bath PMW, Boysen G, et al. SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. *Lancet*. 2011; 377(9767): 741–750, doi: [10.1016/S0140-6736\(11\)60104-9](https://doi.org/10.1016/S0140-6736(11)60104-9), indexed in Pubmed: [21316752](https://pubmed.ncbi.nlm.nih.gov/21316752/).
520. Sandset EC, Murray GD, Bath PMW, et al. Scandinavian Candesartan Acute Stroke Trial (SCAST) Study Group. Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. *Stroke*. 2012; 43(8): 2108–2114, doi: [10.1161/STROKEAHA.111.647362](https://doi.org/10.1161/STROKEAHA.111.647362), indexed in Pubmed: [22627991](https://pubmed.ncbi.nlm.nih.gov/22627991/).
521. ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. *Lancet*. 2015; 385(9968): 617–628, doi: [10.1016/S0140-6736\(14\)61121-1](https://doi.org/10.1016/S0140-6736(14)61121-1), indexed in Pubmed: [25465108](https://pubmed.ncbi.nlm.nih.gov/25465108/).
522. Robinson TG, Potter JF, Ford GA, et al. COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. *Lancet Neurol*. 2010; 9(8): 767–775, doi: [10.1016/S1474-4422\(10\)70163-0](https://doi.org/10.1016/S1474-4422(10)70163-0), indexed in Pubmed: [20621562](https://pubmed.ncbi.nlm.nih.gov/20621562/).
523. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. *Chin Med J (Engl)*. 1995; 108(9): 710–717, indexed in Pubmed: [8575241](https://pubmed.ncbi.nlm.nih.gov/8575241/).
524. White CL, Szychowski JM, Pergola PE, et al. Secondary Prevention of Small Subcortical Strokes Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experience. *J Am Geriatr Soc*. 2015; 63(4): 722–729, doi: [10.1111/jgs.13349](https://doi.org/10.1111/jgs.13349), indexed in Pubmed: [25850462](https://pubmed.ncbi.nlm.nih.gov/25850462/).
525. Kernan WN, Ovbiagele B, Black HR, et al. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014; 45(7): 2160–2236, doi: [10.1161/STR.0000000000000024](https://doi.org/10.1161/STR.0000000000000024), indexed in Pubmed: [24788967](https://pubmed.ncbi.nlm.nih.gov/24788967/).
526. Arima H, Chalmers J, Woodward M, et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. *J Hypertens*. 2006; 24(6): 1201–1208, doi: [10.1097/01.hjh.0000226212.34055.86](https://doi.org/10.1097/01.hjh.0000226212.34055.86), indexed in Pubmed: [16685221](https://pubmed.ncbi.nlm.nih.gov/16685221/).
527. Collier DJ, Poulter NR, Dahlöf B, et al. ASCOT Investigators. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). *J Hypertens*. 2011; 29(3): 583–591, doi: [10.1097/HJH.0b013e328342c845](https://doi.org/10.1097/HJH.0b013e328342c845), indexed in Pubmed: [21297503](https://pubmed.ncbi.nlm.nih.gov/21297503/).
528. National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults. www.nice.org.uk/guidance/CG127 (04.2018).
529. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. *Stroke*. 2002; 33(4): 901–906, indexed in Pubmed: [11935034](https://pubmed.ncbi.nlm.nih.gov/11935034/).
530. Emdin CA, Rothwell PM, Salimi-Khorshidi G, et al. Blood pressure and risk of vascular dementia: evidence from a primary care registry and a cohort study of transient ischemic attack and stroke. *Stroke*. 2016; 47(6): 1429–1435, doi: [10.1161/STROKEAHA.116.012658](https://doi.org/10.1161/STROKEAHA.116.012658), indexed in Pubmed: [27165956](https://pubmed.ncbi.nlm.nih.gov/27165956/).
531. Oishi E, Ohara T, Sakata S, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. *Hypertension*. 2011; 58(1): 22–28, doi: [10.1161/HYPERTENSIONAHA.110.163055](https://doi.org/10.1161/HYPERTENSIONAHA.110.163055), indexed in Pubmed: [21555680](https://pubmed.ncbi.nlm.nih.gov/21555680/).
532. Sierra C, De La Sierra A, Salamero M, et al. Silent cerebral white matter lesions and cognitive function in middle-aged essential hypertensive patients. *Am J Hypertens*. 2004; 17: 529–534.
533. Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. *Alzheimers Dement*. 2015; 11(6): 710–717, doi: [10.1016/j.jalz.2014.10.008](https://doi.org/10.1016/j.jalz.2014.10.008), indexed in Pubmed: [25510382](https://pubmed.ncbi.nlm.nih.gov/25510382/).
534. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. *J Hypertens*. 2013; 31(6): 1073–1082, doi: [10.1097/HJH.0b013e3283603f53](https://doi.org/10.1097/HJH.0b013e3283603f53), indexed in Pubmed: [23552124](https://pubmed.ncbi.nlm.nih.gov/23552124/).
535. Godin O, Tzourio C, Maillard P, et al. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. *Circulation*. 2011; 123(3): 266–273, doi: [10.1161/CIRCULATIONAHA.110.961052](https://doi.org/10.1161/CIRCULATIONAHA.110.961052), indexed in Pubmed: [21220733](https://pubmed.ncbi.nlm.nih.gov/21220733/).
536. Lip GYH, Coca A, Kahan T, et al. Reviewers. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). *Europace*. 2017; 19(6): 891–911, doi: [10.1093/europace/eux091](https://doi.org/10.1093/europace/eux091), indexed in Pubmed: [28881872](https://pubmed.ncbi.nlm.nih.gov/28881872/).
537. Manolis A, Doumas M, Poulimenos L, et al. The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. *J Hypertens*. 2013; 31(11): 2109–17; discussion 2117, doi: [10.1097/HJH.0b013e3283638194](https://doi.org/10.1097/HJH.0b013e3283638194), indexed in Pubmed: [24077242](https://pubmed.ncbi.nlm.nih.gov/24077242/).
538. Laukkanen JA, Khan H, Kurl S, et al. Left ventricular mass and the risk of sudden cardiac death: a population-based study. *J Am Heart Assoc*. 2014; 3(6): e001285, doi: [10.1161/JAHA.114.001285](https://doi.org/10.1161/JAHA.114.001285), indexed in Pubmed: [25376188](https://pubmed.ncbi.nlm.nih.gov/25376188/).
539. Lip GYH. Atrial Fibrillation in Patients With Hypertension: Trajectories of risk factors in yet another manifestation of hypertensive target organ damage. *Hypertension*. 2016; 68(3): 544–545, doi: [10.1161/HYPERTENSIONAHA.116.07901](https://doi.org/10.1161/HYPERTENSIONAHA.116.07901), indexed in Pubmed: [27402920](https://pubmed.ncbi.nlm.nih.gov/27402920/).
540. Conen D, Tedrow UB, Koplan BA, et al. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. *Circulation*. 2009; 119(16): 2146–2152, doi: [10.1161/CIRCULATIONAHA.108.830042](https://doi.org/10.1161/CIRCULATIONAHA.108.830042), indexed in Pubmed: [19364977](https://pubmed.ncbi.nlm.nih.gov/19364977/).
541. Grundvold I, Skretteberg PT, Liestøl K, et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. *Hypertension*. 2012; 59(2):

- 198–204, doi: [10.1161/HYPERTENSIONAHA.111.179713](https://doi.org/10.1161/HYPERTENSIONAHA.111.179713), indexed in Pubmed: [22252392](https://pubmed.ncbi.nlm.nih.gov/22252392/).
542. Lip G, Freedman B, De Caterina R, et al. Stroke prevention in atrial fibrillation. *Lancet*. 2016; 388(10046): 806–817, doi: [10.1016/S0140-6736\(16\)31257-0](https://doi.org/10.1016/S0140-6736(16)31257-0), indexed in Pubmed: [27560276](https://pubmed.ncbi.nlm.nih.gov/27560276/).
543. Schmieder RE, Kjeldsen SE, Julius S, et al. VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. *J Hypertens*. 2008; 26(3): 403–411, doi: [10.1097/HJH.0b013e3282f35c67](https://doi.org/10.1097/HJH.0b013e3282f35c67), indexed in Pubmed: [18300848](https://pubmed.ncbi.nlm.nih.gov/18300848/).
544. Wachtell K, Lehto M, Gerds E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. *J Am Coll Cardiol*. 2005; 45(5): 712–719, doi: [10.1016/j.jacc.2004.10.068](https://doi.org/10.1016/j.jacc.2004.10.068), indexed in Pubmed: [15734615](https://pubmed.ncbi.nlm.nih.gov/15734615/).
545. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med*. 2001; 345(23): 1667–1675, doi: [10.1056/NEJMoa010713](https://doi.org/10.1056/NEJMoa010713), indexed in Pubmed: [11759645](https://pubmed.ncbi.nlm.nih.gov/11759645/).
546. Ducharme A, Swedberg K, Pfeffer MA, et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. *Am Heart J*. 2006; 152(1): 86–92, indexed in Pubmed: [16838426](https://pubmed.ncbi.nlm.nih.gov/16838426/).
547. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SO-LVD) trials. *Circulation*. 2003; 107(23): 2926–2931, doi: [10.1161/01.CIR.0000072793.81076.D4](https://doi.org/10.1161/01.CIR.0000072793.81076.D4), indexed in Pubmed: [12771010](https://pubmed.ncbi.nlm.nih.gov/12771010/).
548. Disertori M, Latini R, Barlera S, et al. GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. *N Engl J Med*. 2009; 360(16): 1606–1617, doi: [10.1056/NEJMoa0805710](https://doi.org/10.1056/NEJMoa0805710), indexed in Pubmed: [19369667](https://pubmed.ncbi.nlm.nih.gov/19369667/).
549. Goette A, Schön N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. *Circ Arrhythm Electrophysiol*. 2012; 5(1): 43–51, doi: [10.1161/CIRCEP.111.965178](https://doi.org/10.1161/CIRCEP.111.965178), indexed in Pubmed: [22157519](https://pubmed.ncbi.nlm.nih.gov/22157519/).
550. Tveit A, Smith P, Seljeflot I, et al. Candesartan in the prevention of relapsing atrial fibrillation. *Int J Cardiol*. 2007; 120(1): 85–91, doi: [10.1016/j.ijcard.2006.08.086](https://doi.org/10.1016/j.ijcard.2006.08.086), indexed in Pubmed: [17113170](https://pubmed.ncbi.nlm.nih.gov/17113170/).
551. Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. *Eur Heart J*. 2007; 28(4): 457–462, doi: [10.1093/eurheartj/ehl484](https://doi.org/10.1093/eurheartj/ehl484), indexed in Pubmed: [17289748](https://pubmed.ncbi.nlm.nih.gov/17289748/).
552. Swedberg K, Zannad F, McMurray JJV, et al. EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) study. *J Am Coll Cardiol*. 2012; 59(18): 1598–1603, doi: [10.1016/j.jacc.2011.11.063](https://doi.org/10.1016/j.jacc.2011.11.063), indexed in Pubmed: [22538330](https://pubmed.ncbi.nlm.nih.gov/22538330/).
553. Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. *Ann Intern Med*. 2010; 152(2): 78–84, doi: [10.7326/0003-4819-152-2-201001190-00005](https://doi.org/10.7326/0003-4819-152-2-201001190-00005), indexed in Pubmed: [20083826](https://pubmed.ncbi.nlm.nih.gov/20083826/).
554. Hung Y, Chao TF, Liu CJ, et al. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)? *J Am Heart Assoc*. 2016; 5(10), doi: [10.1161/JAHA.116.003839](https://doi.org/10.1161/JAHA.116.003839), indexed in Pubmed: [27702803](https://pubmed.ncbi.nlm.nih.gov/27702803/).
555. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? *J Am Coll Cardiol*. 2015; 65(7): 635–642, doi: [10.1016/j.jacc.2014.11.046](https://doi.org/10.1016/j.jacc.2014.11.046), indexed in Pubmed: [25677422](https://pubmed.ncbi.nlm.nih.gov/25677422/).
556. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016; 37(38): 2893–2962, doi: [10.1093/eurheartj/ehw210](https://doi.org/10.1093/eurheartj/ehw210), indexed in Pubmed: [27567408](https://pubmed.ncbi.nlm.nih.gov/27567408/).
557. Mancia G, Parati G, Revere M, et al. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS — a randomized double-blind trial. *Stroke*. 2004; 35(12): 2807–2812, doi: [10.1161/01.STR.0000147041.00840.59](https://doi.org/10.1161/01.STR.0000147041.00840.59), indexed in Pubmed: [15514192](https://pubmed.ncbi.nlm.nih.gov/15514192/).
558. Lorenz MW, Polak JF, Kavousi M, et al. PROG-IMT Study Group. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. *Lancet*. 2012; 379(9831): 2053–2062, doi: [10.1016/S0140-6736\(12\)60441-3](https://doi.org/10.1016/S0140-6736(12)60441-3), indexed in Pubmed: [22541275](https://pubmed.ncbi.nlm.nih.gov/22541275/).
559. Laurent S, Boutouyrie P. Vascular Mechanism Collaboration. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. *Hypertension*. 2014; 64(4): 709–716, doi: [10.1161/HYPERTENSIONAHA.114.03282](https://doi.org/10.1161/HYPERTENSIONAHA.114.03282), indexed in Pubmed: [25001274](https://pubmed.ncbi.nlm.nih.gov/25001274/).
560. Ong KT, Delemer S, Pannier B, et al. investigators. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. *J Hypertens*. 2011; 29(6): 1034–1042, doi: [10.1097/HJH.0b013e328346a583](https://doi.org/10.1097/HJH.0b013e328346a583), indexed in Pubmed: [21519280](https://pubmed.ncbi.nlm.nih.gov/21519280/).
561. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. *Atherosclerosis*. 2012; 221(1): 18–33, doi: [10.1016/j.atherosclerosis.2011.12.005](https://doi.org/10.1016/j.atherosclerosis.2011.12.005), indexed in Pubmed: [22209214](https://pubmed.ncbi.nlm.nih.gov/22209214/).
562. Ait-Oufella H, Collin C, Bozec E, et al. Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice. *J Hypertens*. 2010; 28(11): 2336–2341, doi: [10.1097/HJH.0b013e32833da2b2](https://doi.org/10.1097/HJH.0b013e32833da2b2), indexed in Pubmed: [20683338](https://pubmed.ncbi.nlm.nih.gov/20683338/).
563. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. *Circulation*. 2001; 103(7): 987–992, doi: [10.1161/01.cir.103.7.987](https://doi.org/10.1161/01.cir.103.7.987), indexed in Pubmed: [11181474](https://pubmed.ncbi.nlm.nih.gov/11181474/).
564. Singer DRJ, Kite A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter? *Eur J Vasc Endovasc Surg*. 2008; 35(6): 701–708, doi: [10.1016/j.ejvs.2008.01.007](https://doi.org/10.1016/j.ejvs.2008.01.007), indexed in Pubmed: [18375152](https://pubmed.ncbi.nlm.nih.gov/18375152/).
565. Paravastu SC, Mendonca DA, Da Silva A, et al. Beta blockers for peripheral arterial disease. *Eur J Vasc Endovasc Surg*. 2009; 38(1): 66–70, doi: [10.1016/j.ejvs.2009.02.019](https://doi.org/10.1016/j.ejvs.2009.02.019), indexed in Pubmed: [19359199](https://pubmed.ncbi.nlm.nih.gov/19359199/).
566. Radack K. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. *Arch Intern Med*. 1991; 151(9): 1769, doi: [10.1001/archinte.1991.0040090063012](https://doi.org/10.1001/archinte.1991.0040090063012).
567. Nakamura K, Stefanescu Schmidt A. Treatment of hypertension in coarctation of the aorta. *Curr Treat Options Cardiovasc Med*. 2016; 18(6): 40, doi: [10.1007/s11936-016-0462-x](https://doi.org/10.1007/s11936-016-0462-x), indexed in Pubmed: [27091737](https://pubmed.ncbi.nlm.nih.gov/27091737/).
568. Erbel R, Aboyans V, Boileau C, et al. ESC Committee for Practice Guidelines, The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. *Eur Heart J*. 2014; 35(41): 2873–2926, doi: [10.1093/eurheartj/ehu281](https://doi.org/10.1093/eurheartj/ehu281), indexed in Pubmed: [25173340](https://pubmed.ncbi.nlm.nih.gov/25173340/).
569. Shores J, Berger KR, Murphy EA, et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. *N Engl J Med*. 1994; 330(19): 1335–1341, doi: [10.1056/NEJM199405123301902](https://doi.org/10.1056/NEJM199405123301902), indexed in Pubmed: [8152445](https://pubmed.ncbi.nlm.nih.gov/8152445/).
570. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. *Eur Heart J*. 2013; 34(45): 3491–3500, doi: [10.1093/eurheartj/ehz334](https://doi.org/10.1093/eurheartj/ehz334), indexed in Pubmed: [23999449](https://pubmed.ncbi.nlm.nih.gov/23999449/).
571. Schaefer BM, Lewin MB, Stout KK, et al. The bicuspid aortic valve: an integrated phenotypic classification of leaflet morphology and aortic root shape. *Heart*. 2008; 94(12): 1634–1638, doi: [10.1136/hrt.2007.132092](https://doi.org/10.1136/hrt.2007.132092), indexed in Pubmed: [18308868](https://pubmed.ncbi.nlm.nih.gov/18308868/).
572. Davies RR, Kaple RK, Mandapati D, et al. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. *Ann Thorac Surg*. 2007; 83(4): 1338–1344, doi: [10.1016/j.athoracsur.2006.10.074](https://doi.org/10.1016/j.athoracsur.2006.10.074), indexed in Pubmed: [17383337](https://pubmed.ncbi.nlm.nih.gov/17383337/).

573. Lindman BR, Otto CM. Time to treat hypertension in patients with aortic stenosis. *Circulation*. 2013; 128(12): 1281–1283, doi: [10.1161/CIRCULATIONAHA.113.005275](https://doi.org/10.1161/CIRCULATIONAHA.113.005275), indexed in Pubmed: [23956212](https://pubmed.ncbi.nlm.nih.gov/23956212/).
574. Viigimaa M, Doumas M, Vlachopoulos C, et al. European Society of Hypertension Working Group on Sexual Dysfunction. Hypertension and sexual dysfunction: time to act. *J Hypertens*. 2011; 29(2): 403–407, doi: [10.1097/HJH.0b013e328342c659](https://doi.org/10.1097/HJH.0b013e328342c659), indexed in Pubmed: [21178782](https://pubmed.ncbi.nlm.nih.gov/21178782/).
575. Shamloul R, Ghanem H. Erectile dysfunction. *Lancet*. 2013; 381(9861): 153–165, doi: [10.1016/S0140-6736\(12\)60520-0](https://doi.org/10.1016/S0140-6736(12)60520-0), indexed in Pubmed: [23040455](https://pubmed.ncbi.nlm.nih.gov/23040455/).
576. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. *J Am Coll Cardiol*. 2011; 58(13): 1378–1385, doi: [10.1016/j.jacc.2011.06.024](https://doi.org/10.1016/j.jacc.2011.06.024), indexed in Pubmed: [21920268](https://pubmed.ncbi.nlm.nih.gov/21920268/).
577. La Torre A, Giupponi G, Duffy D, et al. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs. *Pharmacopsychiatry*. 2015; 48(1): 1–6, doi: [10.1055/s-0034-1395515](https://doi.org/10.1055/s-0034-1395515), indexed in Pubmed: [25405774](https://pubmed.ncbi.nlm.nih.gov/25405774/).
578. Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. *Am J Hypertens*. 2004; 17(12 Pt 1): 1135–1142, doi: [10.1016/j.amjhyper.2004.07.004](https://doi.org/10.1016/j.amjhyper.2004.07.004), indexed in Pubmed: [15607620](https://pubmed.ncbi.nlm.nih.gov/15607620/).
579. Foy CG, Newman JC, Berlowitz DR, et al. SPRINT Study Research Group. Blood Pressure, Sexual Activity, and Dysfunction in Women With Hypertension: Baseline findings from the Systolic Blood Pressure Intervention Trial (SPRINT). *J Sex Med*. 2016; 13(9): 1333–1346, doi: [10.1016/j.jsxm.2016.06.014](https://doi.org/10.1016/j.jsxm.2016.06.014), indexed in Pubmed: [27555505](https://pubmed.ncbi.nlm.nih.gov/27555505/).
580. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. *Curr Hypertens Rep*. 2007; 9(4): 320–328, doi: [10.1007/s11906-007-0058-7](https://doi.org/10.1007/s11906-007-0058-7), indexed in Pubmed: [17686384](https://pubmed.ncbi.nlm.nih.gov/17686384/).
581. Abi Aad S, Pierce M, Barmaimon G, et al. Hypertension induced by chemotherapeutic and immunosuppressive agents: a new challenge. *Crit Rev Oncol Hematol*. 2015; 93(1): 28–35, doi: [10.1016/j.critrevonc.2014.08.004](https://doi.org/10.1016/j.critrevonc.2014.08.004), indexed in Pubmed: [25217090](https://pubmed.ncbi.nlm.nih.gov/25217090/).
582. Maitland ML, Bakris GL, Black HR, et al. Cardiovascular Toxicities Panel Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. *J Natl Cancer Inst*. 2010; 102(9): 596–604, doi: [10.1093/jnci/djq091](https://doi.org/10.1093/jnci/djq091), indexed in Pubmed: [20351338](https://pubmed.ncbi.nlm.nih.gov/20351338/).
583. Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management; part 2. *J Am Coll Cardiol*. 2017; 70(20): 2552–2565, doi: [10.1016/j.jacc.2017.09.1095](https://doi.org/10.1016/j.jacc.2017.09.1095), indexed in Pubmed: [29145955](https://pubmed.ncbi.nlm.nih.gov/29145955/).
584. Milan A, Puglisi E, Ferrari L, et al. Arterial hypertension and cancer. *Int J Cancer*. 2014; 134(10): 2269–2277, doi: [10.1002/ijc.28334](https://doi.org/10.1002/ijc.28334), indexed in Pubmed: [23784914](https://pubmed.ncbi.nlm.nih.gov/23784914/).
585. Aronson S, Mythen MG. Perioperative management of high-risk patients: going beyond. *JAMA*. 2017; 318(14): 1330–1332, doi: [10.1001/jama.2017.13699](https://doi.org/10.1001/jama.2017.13699), indexed in Pubmed: [28973071](https://pubmed.ncbi.nlm.nih.gov/28973071/).
586. Kristensen SD, Knuuti J, Saraste A, et al. Authors/Task Force Members, Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). *Eur Heart J*. 2014; 35(35): 2383–2431, doi: [10.1093/eurheartj/ehu282](https://doi.org/10.1093/eurheartj/ehu282), indexed in Pubmed: [25086026](https://pubmed.ncbi.nlm.nih.gov/25086026/).
587. Futier E, Lefrant JY, Guinot PG, et al. INPRESS Study Group. Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery: a randomized clinical trial. *JAMA*. 2017; 318(14): 1346–1357, doi: [10.1001/jama.2017.14172](https://doi.org/10.1001/jama.2017.14172), indexed in Pubmed: [28973220](https://pubmed.ncbi.nlm.nih.gov/28973220/).
588. Bouri S, Shun-Shin MJ, Cole GD, et al. Meta-analysis of secure randomised controlled trials of β -blockade to prevent perioperative death in non-cardiac surgery. *Heart*. 2014; 100(6): 456–464, doi: [10.1136/heartjnl-2013-304262](https://doi.org/10.1136/heartjnl-2013-304262), indexed in Pubmed: [23904357](https://pubmed.ncbi.nlm.nih.gov/23904357/).
589. Blessberger H, Kammler J, Domanovits H, et al. Perioperative β -blockers for preventing surgery-related mortality and morbidity. *Cochrane Database Syst Rev*. 2018; 3: CD004476.
590. Zou Z, Yuan HB, Yang Bo, et al. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults. *Cochrane Database Syst Rev*. 2016(1): CD009210, doi: [10.1002/14651858.CD009210.pub2](https://doi.org/10.1002/14651858.CD009210.pub2), indexed in Pubmed: [26816003](https://pubmed.ncbi.nlm.nih.gov/26816003/).
591. Roshanov PS, Rochweg B, Patel A, et al. Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the vascular events in noncardiac surgery patients cohort evaluation prospective cohort. *Anesthesiology*. 2017; 126(1): 16–27, doi: [10.1097/ALN.0000000000001404](https://doi.org/10.1097/ALN.0000000000001404), indexed in Pubmed: [27775997](https://pubmed.ncbi.nlm.nih.gov/27775997/).
592. London MJ, Hur K, Schwartz GG, et al. Association of perioperative β -blockade with mortality and cardiovascular morbidity following major noncardiac surgery. *JAMA*. 2013; 309(16): 1704–1713, doi: [10.1001/jama.2013.4135](https://doi.org/10.1001/jama.2013.4135), indexed in Pubmed: [23613075](https://pubmed.ncbi.nlm.nih.gov/23613075/).
593. Andersson C, Mérie C, Jørgensen M, et al. Association of β -blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study. *JAMA Intern Med*. 2014; 174(3): 336–344, doi: [10.1001/jamainternmed.2013.11349](https://doi.org/10.1001/jamainternmed.2013.11349), indexed in Pubmed: [24247428](https://pubmed.ncbi.nlm.nih.gov/24247428/).
594. Kwon S, Thompson R, Florence M, et al. Surgical Care and Outcomes Assessment Program (SCOAP) Collaborative. β -blocker continuation after noncardiac surgery: a report from the surgical care and outcomes assessment program. *Arch Surg*. 2012; 147(5): 467–473, doi: [10.1001/archsurg.2011.1698](https://doi.org/10.1001/archsurg.2011.1698), indexed in Pubmed: [22249847](https://pubmed.ncbi.nlm.nih.gov/22249847/).
595. Chapman MJ, Ginsberg HN, Amarenco P, et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J*. 2011; 32(11): 1345–1361, doi: [10.1093/eurheartj/ehr112](https://doi.org/10.1093/eurheartj/ehr112), indexed in Pubmed: [21531743](https://pubmed.ncbi.nlm.nih.gov/21531743/).
596. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT–LLA): a multicentre randomised controlled trial. *Lancet*. 2003; 361(9364): 1149–1158, doi: [10.1016/S0140-6736\(03\)12948-0](https://doi.org/10.1016/S0140-6736(03)12948-0), indexed in Pubmed: [12686036](https://pubmed.ncbi.nlm.nih.gov/12686036/).
597. Ridker PM, Danielson E, Fonseca FAH, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008; 359(21): 2195–2207, doi: [10.1056/NEJMoa0807646](https://doi.org/10.1056/NEJMoa0807646), indexed in Pubmed: [18997196](https://pubmed.ncbi.nlm.nih.gov/18997196/).
598. Yusuf S, Bosch J, Dagenais G, et al. HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med*. 2016; 374(21): 2021–2031, doi: [10.1056/nejmoa1600176](https://doi.org/10.1056/nejmoa1600176).
599. Catapano AL, Graham I, De Backer G, et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*. 2016; 37(39): 2999–3058, doi: [10.1093/eurheartj/ehw272](https://doi.org/10.1093/eurheartj/ehw272), indexed in Pubmed: [27567407](https://pubmed.ncbi.nlm.nih.gov/27567407/).
600. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol*. 2014; 64(5): 485–494, doi: [10.1016/j.jacc.2014.02.615](https://doi.org/10.1016/j.jacc.2014.02.615), indexed in Pubmed: [25082583](https://pubmed.ncbi.nlm.nih.gov/25082583/).
601. Brugs J, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ*. 2009; 338: b2376, doi: [10.1136/bmj.b2376](https://doi.org/10.1136/bmj.b2376), indexed in Pubmed: [19567909](https://pubmed.ncbi.nlm.nih.gov/19567909/).
602. Kritharides L, Nicholls SJ, Fulcher J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet*. 2015; 385(9976): 1397–1405, doi: [10.1016/S0140-6736\(14\)61368-4](https://doi.org/10.1016/S0140-6736(14)61368-4), indexed in Pubmed: [25579834](https://pubmed.ncbi.nlm.nih.gov/25579834/).
603. Lip G. Hypertension and the prothrombotic state. *J Hum Hypertens*. 2000; 14(10-11): 687–690, doi: [10.1038/sj.jhh.1001051](https://doi.org/10.1038/sj.jhh.1001051).

604. Lip GY, Felmeden DC, Dwivedi G, et al. Antiplatelet agents and anticoagulants for hypertension. *Cochrane Database Syst Rev*. 2011; 12: CD003186.
605. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *Eur Heart J*. 2012; 33(12): 1500–1510, doi: [10.1093/eurheartj/ehr488](https://doi.org/10.1093/eurheartj/ehr488), indexed in Pubmed: [22246443](https://pubmed.ncbi.nlm.nih.gov/22246443/).
606. Lip GYH, Andreotti F, Fauchier L, et al. European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. *Thromb Haemost*. 2011; 106(6): 997–1011, doi: [10.1160/TH11-10-0690](https://doi.org/10.1160/TH11-10-0690), indexed in Pubmed: [22048796](https://pubmed.ncbi.nlm.nih.gov/22048796/).
607. Lip GYH, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. *J Thromb Haemost*. 2016; 14(9): 1711–1714, doi: [10.1111/jth.13386](https://doi.org/10.1111/jth.13386), indexed in Pubmed: [27296528](https://pubmed.ncbi.nlm.nih.gov/27296528/).
608. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016; 375(4): 311–322, doi: [10.1056/NEJMoa1603827](https://doi.org/10.1056/NEJMoa1603827), indexed in Pubmed: [27295427](https://pubmed.ncbi.nlm.nih.gov/27295427/).
609. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016; 375(19): 1834–1844, doi: [10.1056/NEJMoa1607141](https://doi.org/10.1056/NEJMoa1607141), indexed in Pubmed: [27633186](https://pubmed.ncbi.nlm.nih.gov/27633186/).
610. Birtwhistle RV, Godwin MS, Delva MD, et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. *BMJ*. 2004; 328(7433): 204, doi: [10.1136/bmj.37967.374063.EE](https://doi.org/10.1136/bmj.37967.374063.EE), indexed in Pubmed: [14726370](https://pubmed.ncbi.nlm.nih.gov/14726370/).
611. Clark CE, Smith LFP, Taylor RS, et al. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. *BMJ*. 2010; 341: c3995, doi: [10.1136/bmj.c3995](https://doi.org/10.1136/bmj.c3995), indexed in Pubmed: [20732968](https://pubmed.ncbi.nlm.nih.gov/20732968/).
612. Bray EP, Holder R, Mant J, et al. Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. *Ann Med*. 2010; 42(5): 371–386, doi: [10.3109/07853890.2010.489567](https://doi.org/10.3109/07853890.2010.489567), indexed in Pubmed: [20504241](https://pubmed.ncbi.nlm.nih.gov/20504241/).
613. Niiranen TJ, Hänninen MR, Johansson J, et al. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. *Hypertension*. 2010; 55(6): 1346–1351, doi: [10.1161/HYPERTENSIONAHA.109.149336](https://doi.org/10.1161/HYPERTENSIONAHA.109.149336), indexed in Pubmed: [20385970](https://pubmed.ncbi.nlm.nih.gov/20385970/).
614. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). *BMJ*. 2007; 334(7599): 885–888, doi: [10.1136/bmj.39147.604896.55](https://doi.org/10.1136/bmj.39147.604896.55), indexed in Pubmed: [17449506](https://pubmed.ncbi.nlm.nih.gov/17449506/).
615. Gupta AK, McGlone M, Greenway FL, et al. Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk profile. *Hypertens Res*. 2010; 33(9): 905–910, doi: [10.1038/hr.2010.91](https://doi.org/10.1038/hr.2010.91), indexed in Pubmed: [20535113](https://pubmed.ncbi.nlm.nih.gov/20535113/).
616. Sacks FM, Svetkey LP, Vollmer WM, et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med*. 2001; 344(1): 3–10, doi: [10.1056/NEJM200101043440101](https://doi.org/10.1056/NEJM200101043440101), indexed in Pubmed: [11136953](https://pubmed.ncbi.nlm.nih.gov/11136953/).
617. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. *JAMA*. 2011; 305(9): 913–922, doi: [10.1001/jama.2011.250](https://doi.org/10.1001/jama.2011.250), indexed in Pubmed: [21364140](https://pubmed.ncbi.nlm.nih.gov/21364140/).
618. Viera AJ, Bangura F, Mitchell CM, et al. Do clinicians tell patients they have prehypertension? *J Am Board Fam Med*. 2011; 24(1): 117–118, doi: [10.3122/jabfm.2011.01.100206](https://doi.org/10.3122/jabfm.2011.01.100206), indexed in Pubmed: [21209353](https://pubmed.ncbi.nlm.nih.gov/21209353/).
619. Gale NK, Greenfield S, Gill P, et al. Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. *BMC Fam Pract*. 2011; 12: 59, doi: [10.1186/1471-2296-12-59](https://doi.org/10.1186/1471-2296-12-59), indexed in Pubmed: [21703010](https://pubmed.ncbi.nlm.nih.gov/21703010/).
620. Krousel-Wood M, Joyce C, Holt E, et al. Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. *Hypertension*. 2011; 58(5): 804–810, doi: [10.1161/HYPERTENSIONAHA.111.176859](https://doi.org/10.1161/HYPERTENSIONAHA.111.176859), indexed in Pubmed: [21968751](https://pubmed.ncbi.nlm.nih.gov/21968751/).
621. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. *Circulation*. 2009; 120(16): 1598–1605, doi: [10.1161/CIRCULATIONAHA.108.830299](https://doi.org/10.1161/CIRCULATIONAHA.108.830299), indexed in Pubmed: [19805653](https://pubmed.ncbi.nlm.nih.gov/19805653/).
622. Burnier M, Wuerzner G, Struijker-Boudier H, et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. *Hypertension*. 2013; 62(2): 218–225, doi: [10.1161/HYPERTENSIONAHA.113.00687](https://doi.org/10.1161/HYPERTENSIONAHA.113.00687), indexed in Pubmed: [23753412](https://pubmed.ncbi.nlm.nih.gov/23753412/).
623. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. *Am J Med*. 2012; 125(9): 882–887.e1, doi: [10.1016/j.amjmed.2011.12.013](https://doi.org/10.1016/j.amjmed.2011.12.013), indexed in Pubmed: [22748400](https://pubmed.ncbi.nlm.nih.gov/22748400/).
624. Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. *Heart*. 2014; 100(11): 855–861, doi: [10.1136/heartjnl-2013-305063](https://doi.org/10.1136/heartjnl-2013-305063), indexed in Pubmed: [24694797](https://pubmed.ncbi.nlm.nih.gov/24694797/).
625. Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. *Hypertension*. 2016; 68(2): 297–306, doi: [10.1161/HYPERTENSIONAHA.116.07464](https://doi.org/10.1161/HYPERTENSIONAHA.116.07464), indexed in Pubmed: [27296995](https://pubmed.ncbi.nlm.nih.gov/27296995/).
626. Burnier M. Managing 'resistance': is adherence a target for treatment? *Curr Opin Nephrol Hypertens*. 2014; 23(5): 439–443, doi: [10.1097/MNH.000000000000045](https://doi.org/10.1097/MNH.000000000000045), indexed in Pubmed: [25036746](https://pubmed.ncbi.nlm.nih.gov/25036746/).
627. Fletcher BR, Hartmann-Boyce J, Hinton L, et al. The Effect of Self-Monitoring of Blood Pressure on Medication Adherence and Lifestyle Factors: A Systematic Review and Meta-Analysis. *Am J Hypertens*. 2015; 28(10): 1209–1221, doi: [10.1093/ajh/hpv008](https://doi.org/10.1093/ajh/hpv008), indexed in Pubmed: [25725092](https://pubmed.ncbi.nlm.nih.gov/25725092/).
628. Burnier M, Brede Y, Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. *Int J Clin Pract*. 2011; 65(2): 127–133, doi: [10.1111/j.1742-1241.2010.02616.x](https://doi.org/10.1111/j.1742-1241.2010.02616.x), indexed in Pubmed: [21208354](https://pubmed.ncbi.nlm.nih.gov/21208354/).
629. Lowy A, Munk VC, Ong SH, et al. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action. *Int J Clin Pract*. 2011; 65(1): 41–53, doi: [10.1111/j.1742-1241.2010.02569.x](https://doi.org/10.1111/j.1742-1241.2010.02569.x), indexed in Pubmed: [21091596](https://pubmed.ncbi.nlm.nih.gov/21091596/).